https://sgo.broadcastmed.io/p/cf/sgo-annual-meeting-on-womens-cancer-3
https://sgo.broadcastmed.io/p/s/bilateral-radical-vulvectomy-with-immediate-bilateral-pudendal-thigh-perforator-flap-reconstruction-indications-complications-and-a-step-by-step-surgical-overview-4
https://sgo.broadcastmed.io/p/s/management-of-high-grade-ovarian-adenocarcinoma-in-an-intraperitoneal-pelvic-renal-transplant-recipient-5
https://sgo.broadcastmed.io/p/s/minimally-invasive-total-vaginectomyiutilizing-robotic-assisted-minimally-invasive-surgery-and-laparoscopic-techniquesifor-the-management-of-malignant-melanoma-in-the-female-reproductive-system-6
https://sgo.broadcastmed.io/p/s/three-dimensional-holographic-imaging-with-augmented-reality-headsets-for-ovarian-cancer-cytoreduction-surgical-planning-7
https://sgo.broadcastmed.io/p/s/placement-of-delayed-absorbable-mesh-to-prevent-herniation-following-left-diaphragm-peritonectomy-during-ovarian-cancer-cytoreduction-8
https://sgo.broadcastmed.io/p/s/ileal-ureter-creation-for-long-segment-ureteral-injury-9
https://sgo.broadcastmed.io/p/s/resection-of-ilio-inguinal-mass-and-reconstruction-with-artificial-vascular-graft-in-vulvar-cancer-recurrence-after-lymphadenectomy-and-radiotherapy-10
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-ix-advancing-care-in-recurrent-low-grade-serous-ovarian-cancer-case-based-approach-verastem-11
https://sgo.broadcastmed.io/p/s/allied-health-forum-impact-of-apps-in-gyn-onc-12
https://sgo.broadcastmed.io/p/s/fwc-poster-walk-and-recap-13
https://sgo.broadcastmed.io/p/s/transition-break-bar-open-14
https://sgo.broadcastmed.io/p/s/tumor-board-how-can-we-leverage-ai-in-our-tumor-boards-and-screening-for-clinical-trials-15
https://sgo.broadcastmed.io/p/s/sgo-social-event-16
https://sgo.broadcastmed.io/p/s/registration-17
https://sgo.broadcastmed.io/p/s/speaker-ready-room-18
https://sgo.broadcastmed.io/p/s/exhibit-hall-open-19
https://sgo.broadcastmed.io/p/s/oral-featured-poster-session-iv-preparing-for-impact-20
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-x-a-treatment-option-for-patients-with-a-certain-type-of-advanced-cervical-cancer-merck-21
https://sgo.broadcastmed.io/p/s/transition-break-22
https://sgo.broadcastmed.io/p/s/business-meeting-and-member-forum-passing-of-the-gavel-23
https://sgo.broadcastmed.io/p/s/focused-forum-xiii-all-things-fda-24
https://sgo.broadcastmed.io/p/s/focused-forum-xiv-molecular-impact-25
https://sgo.broadcastmed.io/p/s/focused-forum-xv-ongoing-impact-26
https://sgo.broadcastmed.io/p/s/oral-featured-poster-session-v-therapeutic-influences-3-2-1-impact-27
https://sgo.broadcastmed.io/p/s/programming-break-coffee-exhibits-and-posters-coffee-and-light-bites-28
https://sgo.broadcastmed.io/p/s/fellows-lounge-programming-wellness-29
https://sgo.broadcastmed.io/p/s/transition-break-30
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-vii-what-clinicians-want-to-know-addressing-current-questions-and-controversies-in-the-management-of-patients-with-ovarian-cancer-research-to-practice-31
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-viii-a-treatment-option-for-patients-with-primary-advanced-or-recurrent-endometrial-cancer-gsk-32
https://sgo.broadcastmed.io/p/s/programming-break-exhibits-and-posters-w-f-and-b-break-33
https://sgo.broadcastmed.io/p/s/poster-tour-group-7-the-rising-impact-of-bench-research-34
https://sgo.broadcastmed.io/p/s/poster-tour-group-8-a-closer-look-at-the-impact-we-are-making-35
https://sgo.broadcastmed.io/p/s/poster-tour-group-9-palliative-considerations-36
https://sgo.broadcastmed.io/p/s/fellows-lounge-programming-finding-your-people-how-to-get-involved-in-sgo-as-a-volunteer-37
https://sgo.broadcastmed.io/p/s/fellows-lounge-programming-contract-negotiation-38
https://sgo.broadcastmed.io/p/s/poster-tour-group-10-pre-clinical-models-39
https://sgo.broadcastmed.io/p/s/poster-tour-group-11-carcinogenesis-and-molecular-analysis-40
https://sgo.broadcastmed.io/p/s/poster-tour-group-12-cervical-cancer-potpourri-41
https://sgo.broadcastmed.io/p/s/focused-forum-x-future-impact-42
https://sgo.broadcastmed.io/p/s/focused-forum-xi-so-you-want-to-be-the-head-of-something-43
https://sgo.broadcastmed.io/p/s/focused-forum-xii-write-like-a-boss-gyn-onc-journal-44
https://sgo.broadcastmed.io/p/s/reception-lgbtqia-plus-and-friends-45
https://sgo.broadcastmed.io/p/s/reception-residentfellowcandidate-46
https://sgo.broadcastmed.io/p/s/reception-allied-reception-new-47
https://sgo.broadcastmed.io/p/s/reception-diversity-48
https://sgo.broadcastmed.io/p/s/opening-reception-49
https://sgo.broadcastmed.io/p/s/in-person-poster-session-presenter-poster-overview-sunday-march-16-2025-from-815-845am-pt-and-210-300pm-pt-50
https://sgo.broadcastmed.io/p/s/virtual-poster-available-on-the-event-platform-51
https://sgo.broadcastmed.io/p/s/industy-supported-symposium-transforming-gynecologic-cancer-treatment-with-antibody-drug-med-learning-group-52
https://sgo.broadcastmed.io/p/s/presidential-invited-speaker-supported-by-abog-liz-wiseman-new-york-times-bestselling-author-53
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-xii-the-impact-of-healthcare-disparities-in-gynecological-malignancies-gsk-medical-54
https://sgo.broadcastmed.io/p/s/poster-tour-group-13-big-data-outcomes-55
https://sgo.broadcastmed.io/p/s/poster-tour-group-14-clinical-trials-impacting-future-therapies-56
https://sgo.broadcastmed.io/p/s/poster-tour-group-15-the-impact-of-social-media-57
https://sgo.broadcastmed.io/p/s/fellows-lounge-programmimg-how-to-navigate-collaboration-with-industry-58
https://sgo.broadcastmed.io/p/s/poster-tour-group-16-pregnancy-and-salpingectomy-impacting-gynecologic-oncology-59
https://sgo.broadcastmed.io/p/s/poster-tour-group-17-perioperative-initiatives-to-impact-surgical-outcomes-60
https://sgo.broadcastmed.io/p/s/poster-tour-group-18-impactful-clinical-trials-mabs-and-small-molecules-61
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-xi-navigating-the-evolving-landscape-of-endometrial-cancer-karyopharm-62
https://sgo.broadcastmed.io/p/s/special-session-using-state-of-the-society-data-to-inform-the-future-of-the-profession-63
https://sgo.broadcastmed.io/p/s/transition-break-64
https://sgo.broadcastmed.io/p/s/scientific-plenary-iv-final-impact-65
https://sgo.broadcastmed.io/p/s/promotion-for-the-2026-annual-meeting-san-juan-puerto-rico-and-closing-ceremony-66
https://sgo.broadcastmed.io/p/s/masterclass-lunch-shared-am-and-pm-sessions-69
https://sgo.broadcastmed.io/p/s/oral-featured-poster-session-i-porque-y-que-impacto-why-and-what-impact-70
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-ii-a-new-era-in-treating-advanced-ovarian-cancer-practical-tips-for-maximizing-the-use-of-parp-inhibitors-immunotherapy-and-adcs-peerview-71
https://sgo.broadcastmed.io/p/s/transition-break-72
https://sgo.broadcastmed.io/p/s/scientific-plenary-ii-hitting-the-target-maximizing-impact-73
https://sgo.broadcastmed.io/p/s/transition-break-74
https://sgo.broadcastmed.io/p/s/focused-forum-i-first-do-no-harm-then-do-good-the-case-for-sustainable-healthcare-jonathan-perlin-md-phd-msha-macp-facmi-the-joint-commission-75
https://sgo.broadcastmed.io/p/s/focused-forum-ii-improving-cervical-cancer-care-expanding-on-whats-old-and-quickly-implementing-whats-new-cervical-cancer-taskforce-76
https://sgo.broadcastmed.io/p/s/focused-forum-iii-pitch-perfect-strategies-to-promote-a-diverse-workforce-how-to-hit-the-high-note-in-health-equity-dihe-committee-77
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-i-exploring-the-horizons-in-endometrial-cancer-biomarkers-guidelines-and-coordinated-care-medscape-llc-78
https://sgo.broadcastmed.io/p/s/transition-break-79
https://sgo.broadcastmed.io/p/s/impact-players-panel-oncology-surgeons-in-the-c-suite-moderators-amanda-fader-md-and-liz-wiseman-new-york-times-bestselling-author-80
https://sgo.broadcastmed.io/p/s/transition-break-81
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-iii-cases-from-the-community-investigators-discuss-the-optimal-management-of-patients-with-her2-positive-gynecologic-cancers-research-to-practice-82
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-iv-maintenance-therapy-in-advanced-ovarian-cancer-results-from-key-clinical-trials-astrazeneca-83
https://sgo.broadcastmed.io/p/s/transition-break-84
https://sgo.broadcastmed.io/p/s/masterclass-high-stakes-communication-around-complex-surgical-decision-making-palliative-care-ticketed-85
https://sgo.broadcastmed.io/p/s/registration-open-86
https://sgo.broadcastmed.io/p/s/speaker-ready-room-87
https://sgo.broadcastmed.io/p/s/masterclass-gynecologic-oncology-is-a-pain-in-the-neck-and-everywhere-else-wellness-committee-ticketed-88
https://sgo.broadcastmed.io/p/s/masterclass-pro-tips-for-a-thriving-practice-and-business-in-gynecologic-oncology-ticketed-89
https://sgo.broadcastmed.io/p/s/masterclass-cracking-the-code-surgical-coding-in-gynecologic-oncology-hpse-committee-ticketed-90
https://sgo.broadcastmed.io/p/s/masterclass-more-than-additive-multiplying-our-impact-in-endometrial-cancer-care-ticketed-91
https://sgo.broadcastmed.io/p/s/masterclass-dominate-in-dallas-masterclass-for-your-oral-boards-sgo-career-development-subcommittee-board-certification-support-ticketed-92
https://sgo.broadcastmed.io/p/s/fwc-patient-and-advocate-education-forum-93
https://sgo.broadcastmed.io/p/s/presidential-address-amanda-nickles-fader-md-94
https://sgo.broadcastmed.io/p/s/workshop-residentfellowcandidate-session-95
https://sgo.broadcastmed.io/p/s/welcome-happy-hour-96
https://sgo.broadcastmed.io/p/s/opening-ceremony-97
https://sgo.broadcastmed.io/p/s/scientific-plenary-i-impactful-trials-improving-patient-care-98
https://sgo.broadcastmed.io/p/s/reception-international-99
https://sgo.broadcastmed.io/p/s/registration-100
https://sgo.broadcastmed.io/p/s/speaker-ready-room-101
https://sgo.broadcastmed.io/p/s/focused-forum-viii-united-nations-of-opportunistic-salpingectomy-102
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-vi-expanding-the-arsenal-innovative-strategies-to-treat-platinum-resistant-ovarian-cancer-corcept-therapeutics-103
https://sgo.broadcastmed.io/p/s/exhibit-hall-open-104
https://sgo.broadcastmed.io/p/s/coffee-exhibits-and-posters-coffee-and-light-bites-105
https://sgo.broadcastmed.io/p/s/fellows-lounge-programming-finding-your-why-navigating-your-career-pathway-106
https://sgo.broadcastmed.io/p/s/poster-tour-group-4-complex-factors-impacting-gyn-cancer-disparities-107
https://sgo.broadcastmed.io/p/s/poster-tour-group-5-impactful-alternative-options-108
https://sgo.broadcastmed.io/p/s/poster-tour-group-6-uterine-cancer-time-to-impactfully-stem-the-tide-109
https://sgo.broadcastmed.io/p/s/focused-forum-vii-equal-impact-110
https://sgo.broadcastmed.io/p/s/industry-supported-symposium-v-building-a-comprehensive-treatment-pathway-in-ovarian-cancer-medscape-education-111
https://sgo.broadcastmed.io/p/s/focused-forum-ix-hashtag-this-20-everything-you-need-to-know-about-launching-your-gynecologic-oncology-social-media-career-112
https://sgo.broadcastmed.io/p/s/oral-featured-poster-session-iii-impacting-lifestyle-113
https://sgo.broadcastmed.io/p/s/workshop-speed-networking-114
https://sgo.broadcastmed.io/p/s/transition-break-115
https://sgo.broadcastmed.io/p/s/korean-society-of-gynecologic-oncology-ksgo-116
https://sgo.broadcastmed.io/p/s/monica-bertagnolli-md-why-are-we-here-117
https://sgo.broadcastmed.io/p/s/exhibit-hall-open-118
https://sgo.broadcastmed.io/p/s/scientific-plenary-iii-race-for-impact-late-breaking-abstracts-119
https://sgo.broadcastmed.io/p/s/transition-break-120
https://sgo.broadcastmed.io/p/s/focused-forum-iv-finding-impact-the-needle-in-the-haystack-121
https://sgo.broadcastmed.io/p/s/focused-forum-v-decentralized-clinical-trials-122
https://sgo.broadcastmed.io/p/s/focused-forum-vi-farr-nezhat-surgical-innovation-session-123
https://sgo.broadcastmed.io/p/s/gender-equity-session-film-screening-and-open-forum-trans-dudes-with-lady-cancer-dihe-committee-124
https://sgo.broadcastmed.io/p/s/oral-featured-poster-session-ii-multiple-ways-to-make-an-impact-125
https://sgo.broadcastmed.io/p/s/fellows-lounge-programing-program-directors-126
https://sgo.broadcastmed.io/p/s/poster-tour-group-1-gyn-oncology-fellowship-contemporary-changes-whats-the-impact-127
https://sgo.broadcastmed.io/p/s/poster-tour-group-2-modulating-immunotherapy-impact-128
https://sgo.broadcastmed.io/p/s/poster-tour-group-3-emerging-impact-in-clinical-trials-and-their-methodology-129
https://sgo.broadcastmed.io/p/s/roaring-20s-presidents-reception-invite-only-130
https://sgo.broadcastmed.io/p/s/registration-131
https://sgo.broadcastmed.io/p/s/speaker-ready-room-132
https://sgo.broadcastmed.io/p/cf/sgo-annual-meeting-on-womens-cancer-posters-133
https://sgo.broadcastmed.io/p/s/improving-disparities-by-implementing-a-supportive-care-program-population-served-health-care-utilization-and-cost-134
https://sgo.broadcastmed.io/p/s/how-are-we-caring-for-the-oldest-ovarian-cancer-patients-evaluating-post-ewoc-1-adaptations-and-oncologic-decision-making-135
https://sgo.broadcastmed.io/p/s/waiting-for-gyn-onc-inefficient-referral-patterns-and-treatment-delays-for-patients-with-limited-english-proficiency-136
https://sgo.broadcastmed.io/p/s/knowledge-of-cancer-as-an-etiology-for-abnormal-uterine-bleeding-aub-is-low-among-women-at-increased-risk-for-endometrial-cancer-137
https://sgo.broadcastmed.io/p/s/race-and-ethnicity-based-disparities-in-chemoradiation-timing-among-cervical-cancer-patients-138
https://sgo.broadcastmed.io/p/s/update-phase-i-clinical-trial-to-assess-safety-tolerability-and-feasibility-of-pngvl4acrte6e7l2-hpv-dna-vaccine-administration-via-intramuscular-trigrid-electroporation-delivery-system-to-patients-wit-139
https://sgo.broadcastmed.io/p/s/association-of-a-homologous-recombination-deficiency-signature-with-oncologic-outcomes-in-advanced-endometrial-cancer-140
https://sgo.broadcastmed.io/p/s/neoadjuvant-chemotherapy-followed-by-chemoradiation-plus-adjuvant-chemotherapy-for-locally-advanced-cervical-cancer-a-real-world-study-with-10-years-experience-141
https://sgo.broadcastmed.io/p/s/ancestry-based-disparities-in-variants-of-uncertain-significance-vus-among-patients-with-ovarian-cancer-undergoing-genetic-testing-142
https://sgo.broadcastmed.io/p/s/rad52-inhibition-enhances-olaparib-efficacy-in-parp-inhibitor-resistant-brca-deficient-ovarian-cancer-143
https://sgo.broadcastmed.io/p/s/predicting-lymph-node-metastasis-in-low-risk-cervical-cancer-patients-do-all-patients-with-stage-ia2-ib1-require-surgical-nodal-evaluation-144
https://sgo.broadcastmed.io/p/s/ak104-combined-with-concurrent-chemoradiotherapy-for-the-treatment-of-locally-advanced-cervi-145
https://sgo.broadcastmed.io/p/s/genomic-and-immunohistochemical-characterization-of-nsmp-endometrial-cancer-a-novel-approach-to-estrogen-receptor-positivity-146
https://sgo.broadcastmed.io/p/s/the-safety-and-feasibility-of-a-novel-preoperative-weight-loss-program-in-patients-with-obesity-and-atypical-hyperplasia-or-low-grade-endometrial-carcinoma-147
https://sgo.broadcastmed.io/p/s/metformin-with-the-levonorgestrel-releasing-intrauterine-device-for-the-treatment-of-endometrial-intraepithelial-neoplasia-and-endometrial-cancer-in-non-surgical-patients-148
https://sgo.broadcastmed.io/p/s/exploring-facets-of-quality-of-life-of-women-experiencing-recurrent-ovarian-cancer-why-does-it-matter-149
https://sgo.broadcastmed.io/p/s/insulin-resistance-and-endometrial-cancer-risk-in-postmenopausal-women-by-race-and-body-mass-index-150
https://sgo.broadcastmed.io/p/s/comprehensive-risk-reduction-improving-menopausal-healthcare-surrounding-prophylactic-oophorectomy-151
https://sgo.broadcastmed.io/p/s/comparative-effects-of-glp-1-receptor-agonists-combined-with-hormonal-therapy-on-endometrial-cancer-risk-in-women-with-benign-uterine-or-hyperplasia-a-us-real-world-retrospective-study-152
https://sgo.broadcastmed.io/p/s/comparison-of-two-adjuvant-high-dose-rate-vaginal-cuff-brachytherapy-dose-fractionation-regimens-for-treatment-of-early-stage-uterine-cancera-euro-153
https://sgo.broadcastmed.io/p/s/increasing-the-scope-of-ovarian-cancer-prevention-an-evaluation-of-interest-in-opportunistic-salpingectomy-among-patients-scheduled-for-non-gynecologic-abdominal-surgery-154
https://sgo.broadcastmed.io/p/s/impact-of-chemotherapy-and-radiotherapy-on-sexual-health-in-cervical-cancer-patients-a-single-center-study-155
https://sgo.broadcastmed.io/p/s/endomyometrial-resection-for-fertility-preservation-in-patients-with-progestin-resistant-atypical-hyperplasia-or-grade-1-endometrioid-endometrial-cancer-156
https://sgo.broadcastmed.io/p/s/gynecologic-oncology-fellowship-trends-supply-outpacing-demand-geographical-maldistribution-157
https://sgo.broadcastmed.io/p/s/fit4surgery-a-pilot-randomized-control-trial-to-evaluate-the-role-of-prehabiliation-prior-to-debulking-surgery-for-ovarian-cancer-158
https://sgo.broadcastmed.io/p/s/improved-physical-and-emotional-health-in-patients-with-advanced-ovarian-cancer-undergoing-prehabilitation-159
https://sgo.broadcastmed.io/p/s/the-decline-of-radical-hysterectomies-performed-by-gynecologic-oncologists-in-the-united-states-2004-2020-160
https://sgo.broadcastmed.io/p/s/pregnancies-in-gynecologic-oncologists-an-assessment-of-pregnancy-policies-and-complications-within-a-surgical-subspecialty-161
https://sgo.broadcastmed.io/p/s/assessing-progress-towards-gender-equity-among-principal-investigators-of-gynecologic-oncology-clinical-trials-and-inclusion-of-racially-and-ethnically-diverse-trial-participants-162
https://sgo.broadcastmed.io/p/s/functional-precision-medicine-profiling-of-patient-derived-organoids-identifies-effective-targeted-therapies-for-patients-with-low-grade-serous-ovarian-carcinoma-163
https://sgo.broadcastmed.io/p/s/pamiparib-in-combination-with-surufatinib-in-patients-with-platinum-resistant-ovarian-cancer-who-received-prior-parp-inhibitors-a-multicenter-single-arm-phase-ibii-trial-post-parpi-trial-164
https://sgo.broadcastmed.io/p/s/high-p53-and-nmnat2-expression-levels-correlate-with-parp-inhibitor-resistance-in-endometrial-cancer-cells-165
https://sgo.broadcastmed.io/p/s/optimal-adjuvant-treatment-modality-in-low-grade-serous-ovarian-cancer-a-national-cancer-database-study-166
https://sgo.broadcastmed.io/p/s/translational-studies-of-copanira-a-phase-ib-trial-of-copanlisib-pi3k-inhibitor-and-niraparib-parp-inhibitor-in-recurrent-ovarian-and-endometrial-cancer-167
https://sgo.broadcastmed.io/p/s/mechanisms-of-resistance-to-anti-muc16-mmae-antibody-drug-conjugate-therapy-in-ovarian-cancer-168
https://sgo.broadcastmed.io/p/s/novel-insights-into-age-specific-incidence-rates-of-uterine-cancer-by-histologic-subtype-and-race-and-ethnicity-169
https://sgo.broadcastmed.io/p/s/veterans-with-gynecologic-cancer-2004-2021-a-national-cancer-database-study-170
https://sgo.broadcastmed.io/p/s/development-of-a-genetically-induced-syngeneic-mouse-model-of-endometrial-cancer-171
https://sgo.broadcastmed.io/p/s/the-impact-of-romiplostim-use-for-chemotherapy-induced-thrombocytopenia-on-immediate-and-long-term-outcomes-in-gynecologic-malignancies-172
https://sgo.broadcastmed.io/p/s/impact-of-re1-silencing-transcription-factor-rest-and-obesity-on-endometrial-pathology-and-associated-biomarkers-in-mice-173
https://sgo.broadcastmed.io/p/s/racial-and-ethnic-disparities-in-debulking-surgery-and-complete-cytoreduction-among-ovarian-cancer-patients-174
https://sgo.broadcastmed.io/p/s/successful-bilateral-sentinel-lymph-node-mapping-rate-in-uterine-cancer-by-body-mass-index-and-surgical-approach-175
https://sgo.broadcastmed.io/p/s/empty-nodal-packet-rate-in-patients-undergoing-sentinel-lymph-node-assessment-for-uterine-cancer-176
https://sgo.broadcastmed.io/p/s/feasibility-and-acceptability-of-a-mind-body-movement-based-intervention-developed-with-and-for-endometrial-cancer-survivors-177
https://sgo.broadcastmed.io/p/s/the-lived-experience-and-patient-driven-iterations-to-improve-a-novel-preoperative-weight-loss-intervention-in-patients-with-endometrial-cancer-and-obesitya-178
https://sgo.broadcastmed.io/p/s/interrogation-of-exosome-mediated-intercellular-signaling-and-pre-metastatic-niche-establishment-for-diagnostic-biomarkers-in-patients-with-ovarian-cancer-179
https://sgo.broadcastmed.io/p/s/prognostic-utility-of-peritoneal-cytology-in-patients-with-2009-figo-stage-i-uterine-serous-carcinoma-180
https://sgo.broadcastmed.io/p/s/combination-of-carboplatin-and-chk1-inhibition-to-overcome-platinum-resistance-in-high-grade-serous-ovarian-cancer-181
https://sgo.broadcastmed.io/p/s/lets-code-it-evaluation-of-social-determinations-of-health-icd-9-and-icd-10-coding-in-gynecologic-oncology-182
https://sgo.broadcastmed.io/p/s/chemoradiation-after-chemotherapy-for-metastatic-cervical-cancer-can-provide-treatment-free-time-183
https://sgo.broadcastmed.io/p/s/gpr171-a-prognostic-marker-of-improved-survival-in-cervix-cancer-a-deep-south-consortium-in-oncology-dsco-project-184
https://sgo.broadcastmed.io/p/s/a-critical-role-of-intracellular-pd-l1-in-promoting-ovarian-cancer-progression-185
https://sgo.broadcastmed.io/p/s/cervical-cancer-screening-patterns-and-outcomes-in-women-65-years-old-a-retrospective-study-of-medicare-patients-186
https://sgo.broadcastmed.io/p/s/should-we-advocate-for-continued-availability-of-actinomycin-d-to-remain-an-essential-first-line-treatment-for-low-risk-gestational-trophoblastic-neoplasia-187
https://sgo.broadcastmed.io/p/s/radiotherapy-at-the-end-of-life-for-patients-with-gynecologic-malignancies-a-12-year-population-based-retrospective-analysis-188
https://sgo.broadcastmed.io/p/s/obesity-and-ovarian-cancer-leveraging-real-world-data-for-incidence-and-outcomes-using-a-multicenter-nationwide-electronic-database-189
https://sgo.broadcastmed.io/p/s/trends-in-research-productivity-among-incoming-gynecologic-oncology-fellows-190
https://sgo.broadcastmed.io/p/s/trends-in-physical-activity-for-ovarian-cancer-survivors-completing-primary-therapy-191
https://sgo.broadcastmed.io/p/s/iov-end-201-a-phase-2-multicenter-open-label-study-of-lifileucel-tumor-infiltrating-lymphocytes-til-in-participants-with-previously-treated-advanced-endometrial-cancer-192
https://sgo.broadcastmed.io/p/s/the-effectiveness-of-intraperitoneal-carboplatin-taxane-combination-chemotherapy-in-patients-with-ovarian-cancer-193
https://sgo.broadcastmed.io/p/s/gog-3068hott-randomized-trial-of-hipec-with-cisplatin-at-interval-cytoreductive-surgery-followed-by-niraparib-maintenance-in-patients-with-newly-diagnosed-stage-iii-and-iv-ovarian-primary-peritoneal-a-194
https://sgo.broadcastmed.io/p/s/concordance-between-foundation-medicine-homologous-recombination-deficiency-signature-hrdsig-and-myriad-genomic-instability-score-gis-195
https://sgo.broadcastmed.io/p/s/phase-ii-trial-of-niraparib-in-combination-with-dostarlimab-in-patients-with-recurrent-or-progressive-cervix-cancer-star-196
https://sgo.broadcastmed.io/p/s/high-concordance-between-immunohistochemistry-ihc-and-next-generation-sequencing-ngs-for-determining-tp53-mutation-status-in-endometrial-cancer-ec-a-post-hoc-analysis-of-the-engot-en5gog-3055siendo-st-197
https://sgo.broadcastmed.io/p/s/anti-agal-antibodies-as-an-adjunct-prognostic-marker-to-ca125-muc16-in-epithelial-ovarian-cancers-198
https://sgo.broadcastmed.io/p/s/trofuse-020gog-3101engot-cx20-a-phase-3-randomized-active-controlled-open-label-multicenter-study-comparing-sacituzumab-tirumotecan-monotherapy-vs-treatment-of-physiciana-euro-s-choice-as-second-line--199
https://sgo.broadcastmed.io/p/s/trials-in-progress-perioperative-stress-reduction-in-ovarian-cancer-preserve-trial-200
https://sgo.broadcastmed.io/p/s/homozygous-loss-of-homologous-repair-genes-and-durable-benefit-from-parpi-maintenance-mparpi-for-patients-with-ovarian-cancer-oc-201
https://sgo.broadcastmed.io/p/s/does-facility-volume-improve-overall-survival-in-patients-with-advanced-vulvar-cancer-202
https://sgo.broadcastmed.io/p/s/phase-i-trial-of-single-dose-intravenous-vesicular-stomatitis-virus-vsv-hifnv-nis-in-patients-with-advanced-or-recurrent-endometrial-cancer-203
https://sgo.broadcastmed.io/p/s/evaluating-the-role-of-social-determinants-of-health-in-consideration-of-patient-selection-for-gynecological-cancer-treatment-trials-a-community-cancer-center-perspective-204
https://sgo.broadcastmed.io/p/s/alc1-loss-expands-the-therapeutic-utility-of-parp-inhibitors-in-high-grade-serous-ovarian-cancer-205
https://sgo.broadcastmed.io/p/s/uterine-cancer-diagnosis-at-age-65-onset-of-medicare-eligibility-and-impact-of-medicaid-expansion-206
https://sgo.broadcastmed.io/p/s/peer-influence-on-physicians-in-adopting-opportunistic-salpingectomy-for-sterilization-207
https://sgo.broadcastmed.io/p/s/comparative-analysis-of-laparoscopic-versus-open-inguinal-lymphadenectomy-in-vulvar-cancer-surgery-from-single-cancer-center-ten-years-data-208
https://sgo.broadcastmed.io/p/s/a-cross-sectional-study-of-cervical-cancer-screening-rates-within-a-large-national-network-of-community-health-organizations-209
https://sgo.broadcastmed.io/p/s/is-uterine-serous-carcinoma-an-exclusively-postmenopausal-disease-unveiling-a-distinct-age-specific-oncologic-pattern-210
https://sgo.broadcastmed.io/p/s/cytoreductive-surgery-for-recurrent-low-grade-ovarian-cancer-211
https://sgo.broadcastmed.io/p/s/penelope-a-randomized-phase-ii-trial-of-first-line-carboplatin-and-paclitaxel-in-combination-with-pembrolizumab-followed-by-maintenance-pembrolizumab-with-or-without-nesuparib-in-patients-with-newly-d-212
https://sgo.broadcastmed.io/p/s/ascites-as-a-predictor-of-optimal-cytoreduction-in-ovarian-cancer-a-national-cancer-database-study-213
https://sgo.broadcastmed.io/p/s/government-funding-for-uterine-cancer-research-lags-behind-rising-incidence-214
https://sgo.broadcastmed.io/p/s/racial-differences-in-next-generation-tumor-sequencing-among-cervical-cancer-patients-215
https://sgo.broadcastmed.io/p/s/exploring-the-impact-of-circulating-inflammatory-proteins-on-cervical-cancer-lesion-progression-a-two-sample-bidirectional-mendelian-randomization-study-216
https://sgo.broadcastmed.io/p/s/a-nomogram-for-predicting-overall-survival-in-patients-with-clear-cell-adenocarcinoma-of-the-cervix-a-population-based-analysis-217
https://sgo.broadcastmed.io/p/s/anlotinib-enhances-immunotherapy-efficacy-in-pik3ca-mutant-cervical-cancer-by-inhibiting-rps26-mediated-activation-of-the-pi3kakt-pathway-218
https://sgo.broadcastmed.io/p/s/long-term-outcomes-of-local-tumor-destructionexcision-not-inferior-to-total-hysterectomy-for-stage-ia-cervical-cancer-a-retrospective-cohort-study-with-propensity-score-matching-analysis-219
https://sgo.broadcastmed.io/p/s/anlotinib-plus-penpulimab-plus-chemo-less-therapy-in-first-line-treatment-for-persistent-recurrent-or-metastatic-cervical-cancer-a-single-arm-open-label-phase-a-study-altn-ak105-ii-06-220
https://sgo.broadcastmed.io/p/s/cytoreductive-approach-of-advanced-epithelial-ovarian-cancer-and-survival-outcomes-a-real-world-single-center-analysis-221
https://sgo.broadcastmed.io/p/s/progression-free-survival-for-interval-debulking-surgery-for-epithelial-ovarian-cancer-is-not-impacted-by-minimally-invasive-surgery-222
https://sgo.broadcastmed.io/p/s/comprehensive-genomic-profiling-cgp-of-folr1-positive-ovarian-cancer-223
https://sgo.broadcastmed.io/p/s/prognostic-significance-of-thoracic-lesions-in-ovarian-cancer-patients-in-the-era-of-chronic-medical-management-224
https://sgo.broadcastmed.io/p/s/the-pynnacle-phase-2-trial-assessing-rezatapopt-pc14586-a-selective-p53-reactivator-in-patients-with-locally-advanced-or-metastatic-solid-tumors-including-ovarian-and-endometrial-cancers-harboring-a-t-225
https://sgo.broadcastmed.io/p/s/sexual-health-after-surgical-menopause-long-term-impact-of-provider-education-on-peri-operative-counseling-226
https://sgo.broadcastmed.io/p/s/minimally-invasive-primary-staging-surgery-for-early-stage-ovarian-cancer-a-systematic-review-and-meta-analysis-227
https://sgo.broadcastmed.io/p/s/surgery-versus-definitive-radiotherapy-in-the-management-of-early-stage-small-cell-neuroendocrine-carcinoma-of-the-cervix-a-systematic-review-and-meta-analysis-228
https://sgo.broadcastmed.io/p/s/nutrition-risk-stratification-using-the-patient-generated-subjective-global-assessment-in-patients-with-gynecologic-malignancies-in-the-outpatient-setting-229
https://sgo.broadcastmed.io/p/s/arid1a-as-a-clinical-biomarker-of-immunotherapy-response-in-gynecologic-cancer-230
https://sgo.broadcastmed.io/p/s/datopotomab-deruxtecan-dato-dxd-a-trop2-directed-antibody-drug-conjugate-demonstrates-antitumor-activity-in-uterine-serous-carcinoma-231
https://sgo.broadcastmed.io/p/s/role-of-systematic-lymphadenectomy-at-time-of-cytoreductive-surgery-among-non-high-grade-serous-epithelial-ovarian-cancers-232
https://sgo.broadcastmed.io/p/s/cops5-depletion-via-csn5i-3-downregulates-dna-damage-repair-to-synergize-with-poly-adp-ribose-polymerase-inhibitors-233
https://sgo.broadcastmed.io/p/s/the-impact-of-malnutrition-on-post-operative-complications-in-patients-with-ovarian-cancer-a-nsqip-analysis-234
https://sgo.broadcastmed.io/p/s/real-world-safety-and-efficacy-of-combination-chemotherapy-and-dostarlimab-in-advanced-endometrial-cancer-235
https://sgo.broadcastmed.io/p/s/phase-2-study-of-dostarlimab-in-combination-with-cobolimab-in-advanced-cervical-cancer-236
https://sgo.broadcastmed.io/p/s/a-molecular-comparison-reveals-distinct-transcriptomic-differences-between-uterine-carcinosarcoma-and-papillary-serous-carcinoma-distinguishable-by-dna-damage-237
https://sgo.broadcastmed.io/p/s/spatial-genomic-analysis-of-lynch-and-non-lynch-endometrial-cancers-reveals-key-differences-in-the-tumor-immune-microenvironment-238
https://sgo.broadcastmed.io/p/s/relationship-between-hemoglobin-a1c-screening-and-complication-rates-following-surgical-oncology-and-gynecologic-oncology-surgery-239
https://sgo.broadcastmed.io/p/s/predictors-of-blood-transfusion-for-stage-i-endometrial-cancer-patients-undergoing-surgical-management-240
https://sgo.broadcastmed.io/p/s/substantial-missed-opportunities-for-prevention-of-ovarian-cancer-a-need-for-expansion-of-opportunistic-salpingectomy-241
https://sgo.broadcastmed.io/p/s/enhanced-recovery-program-adherence-following-gynecologic-oncology-surgery-is-decreased-in-those-with-increasing-social-vulnerability-242
https://sgo.broadcastmed.io/p/s/streamlining-acute-care-for-patients-with-gynecologic-cancers-a-comparative-study-of-oncology-urgent-care-and-emergency-department-visits-243
https://sgo.broadcastmed.io/p/s/analysis-of-tumor-homologous-recombination-deficiency-results-and-germline-carrier-status-in-individuals-with-brca-and-non-brca-hrd-pathway-mutations-in-a-laboratory-based-research-registry-244
https://sgo.broadcastmed.io/p/s/minimizing-excess-post-operative-opioid-prescriptions-in-gynecologic-oncology-patients-245
https://sgo.broadcastmed.io/p/s/highlights-and-challenges-to-enhanced-recovery-after-surgery-eras-in-gynecologic-oncology-hysterectomies-performed-at-a-community-hospital-246
https://sgo.broadcastmed.io/p/s/gynecologic-cancer-clinical-trials-from-2005-to-2023-trends-limitations-and-opportunities-247
https://sgo.broadcastmed.io/p/s/public-health-insurance-is-adversely-associated-with-survival-outcomes-in-patients-with-endometrial-cancer-248
https://sgo.broadcastmed.io/p/s/evaluating-the-prognostic-role-of-lymphovascular-space-invasion-in-figo-2009-stage-i-endometrioid-endometrial-cancer-according-to-depth-of-myoinvasion-249
https://sgo.broadcastmed.io/p/s/preferences-of-brca-mutation-carriers-for-attributes-of-risk-reducing-surgical-options-for-breast-and-ovarian-cancer-250
https://sgo.broadcastmed.io/p/s/cohort-effects-of-changes-in-premenopausal-hysterectomy-on-subsequent-uterine-cancer-incidence-251
https://sgo.broadcastmed.io/p/s/somatic-mutation-analysis-via-next-generation-sequencing-of-paired-primary-and-metastatic-tumor-samples-of-high-grade-epithelial-ovarian-carcinomas-252
https://sgo.broadcastmed.io/p/s/association-of-adc-values-on-mri-with-tp53-mutations-in-women-with-high-grade-serous-ovarian-cancer-preliminary-results-of-an-observational-study-253
https://sgo.broadcastmed.io/p/s/histology-as-a-predictor-of-line-1-expression-in-endometrial-cancer-254
https://sgo.broadcastmed.io/p/s/integrated-genomic-approaches-to-characterize-biological-responses-to-mek-inhibition-and-mechanisms-of-therapeutic-resistance-in-lgsoc-255
https://sgo.broadcastmed.io/p/s/county-level-variation-in-gynecologic-cancer-mortality-and-associations-with-county-population-and-health-system-characteristics-in-the-united-states-2001-2020-256
https://sgo.broadcastmed.io/p/s/dissecting-racial-disparities-in-uterine-cancer-incidence-and-mortality-in-the-united-states-comparisons-trends-and-small-area-variation-257
https://sgo.broadcastmed.io/p/s/fragmentation-of-postoperative-care-following-gynecologic-cancer-surgery-is-associated-with-adverse-outcomes-and-higher-costs-258
https://sgo.broadcastmed.io/p/s/receipt-of-adjuvant-radiotherapy-increases-survival-in-2009-figo-stage-i-patients-with-endometrial-cancer-upstaged-according-to-the-figo-2023-guidelines-259
https://sgo.broadcastmed.io/p/s/endometrial-intraepithelial-neoplasia-ein-as-a-precursor-in-lynch-syndrome-associated-endometrial-carcinoma-260
https://sgo.broadcastmed.io/p/s/clinical-and-histological-characteristics-of-lynch-syndrome-associated-endometrial-cancer-261
https://sgo.broadcastmed.io/p/s/extending-the-hispaniclatinx-paradox-to-hispanic-white-vs-non-hispanic-white-patients-with-stage-i-iv-cervical-carcinoma-262
https://sgo.broadcastmed.io/p/s/development-and-initial-clinical-testing-of-a-multiplexed-circulating-tumor-cell-assay-in-patients-with-epithelial-ovarian-carcinoma-as-a-predictive-biomarker-of-optimal-cytoreduction-263
https://sgo.broadcastmed.io/p/s/time-to-catch-up-post-pandemic-trends-in-hpv-vaccination-rates-among-adolescents-264
https://sgo.broadcastmed.io/p/s/noncompete-agreements-in-employment-contracts-knowledge-and-opinions-of-practicing-gynecologic-oncologist-members-of-sgo-265
https://sgo.broadcastmed.io/p/s/preclinical-development-of-novel-small-molecule-multitarget-inhibitors-lci133-for-endometrial-adenocarcinoma-266
https://sgo.broadcastmed.io/p/s/association-of-neutrophil-to-lymphocyte-ratio-and-ca125-with-sensitivity-to-platinum-based-chemotherapy-in-patients-with-epithelial-ovarian-carcinoma-267
https://sgo.broadcastmed.io/p/s/the-downfall-of-the-covid-19-pandemic-hpv-vaccination-rates-in-hispanic-populations-in-the-united-states-268
https://sgo.broadcastmed.io/p/s/quality-of-life-as-a-survival-indicator-in-gynecologic-cancers-a-systematic-review-269
https://sgo.broadcastmed.io/p/s/genomic-characteristics-of-pole-mutations-in-endometrial-cancer-a-single-institution-study-270
https://sgo.broadcastmed.io/p/s/risk-factors-for-high-grade-squamous-intraepithelial-lesion-recurrence-after-the-two-layer-loop-electrosurgical-excision-procedure-in-patients-with-positive-endocervical-exocervical-and-deep-margins-271
https://sgo.broadcastmed.io/p/s/endometrial-cancer-survival-outcomes-by-mmr-status-in-a-diverse-cohort-272
https://sgo.broadcastmed.io/p/s/mmr-status-and-race-is-there-an-association-273
https://sgo.broadcastmed.io/p/s/outcomes-post-operative-complications-and-quality-of-life-in-patients-receiving-hyperthermic-intraperitoneal-chemotherapy-hipec-for-epithelial-ovarian-cancer-274
https://sgo.broadcastmed.io/p/s/beneath-the-layers-association-of-preoperative-sarcopenia-with-postoperative-discharge-destination-and-icu-admission-in-patients-with-ovarian-cancer-275
https://sgo.broadcastmed.io/p/s/randomized-pilot-clinical-trial-of-neuroplasticity-based-computer-exercises-for-gynecologic-cancer-related-cognitive-impairment-gyncog-276
https://sgo.broadcastmed.io/p/s/germline-and-somatic-testing-in-patients-with-endometrial-carcinosarcoma-and-impact-of-tp53-somatic-mutation-on-survival-277
https://sgo.broadcastmed.io/p/s/the-effects-of-glucagon-like-peptide-1-receptor-agonists-on-incident-gynecological-cancer-outcomes-in-endometriosis-patients-compared-to-metformin-a-real-world-multi-center-retrospective-cohort-study--278
https://sgo.broadcastmed.io/p/s/optimal-biomarkers-derived-from-preoperative-ct-scans-to-predict-postoperative-morbidity-in-patients-with-ovarian-cancer-279
https://sgo.broadcastmed.io/p/s/clinicopathologic-features-of-mesonephric-like-adenocarcinoma-of-the-ovary-and-peritoneum-280
https://sgo.broadcastmed.io/p/s/efficacy-of-apixaban-for-postoperative-thromboprophylaxis-after-laparotomy-in-gynecologic-oncology-patients-with-elevated-body-mass-index-281
https://sgo.broadcastmed.io/p/s/outcomes-following-levonogestrel-intrauterine-device-use-in-women-with-endometrial-intraepithelial-neoplasia-or-adenocarcinoma-in-an-urban-teritary-care-network-a-10-year-retrospective-study-282
https://sgo.broadcastmed.io/p/s/modification-of-the-tumor-myeloid-compartment-by-cxcr2-inhibition-283
https://sgo.broadcastmed.io/p/s/geographic-disparities-in-access-to-gynecologic-oncologist-subspecialty-care-284
https://sgo.broadcastmed.io/p/s/randomized-pilot-study-assessing-the-safety-and-tolerability-of-chemotherapy-prior-to-interval-cytoreductive-surgery-versus-hyperthermic-intraperitoneal-chemotherapy-hipec-at-completion-of-surgery-for-285
https://sgo.broadcastmed.io/p/s/the-effect-of-low-frequency-soundwave-stimulation-on-chemotherapy-induced-peripheral-neuropathy-286
https://sgo.broadcastmed.io/p/s/socioeconomic-segregation-and-disparities-in-cervical-cancer-survival-an-analysis-of-index-of-concentration-at-the-extremes-287
https://sgo.broadcastmed.io/p/s/factors-associated-with-increased-surgical-morbidity-and-mortality-in-gynecologic-oncology-patients-80-years-old-288
https://sgo.broadcastmed.io/p/s/rationale-and-study-design-of-the-kov-hipec-04-a-phase-iii-randomized-controlled-trial-in-primary-stage-three-and-four-ovarian-cancer-after-interval-cytoreductive-surgery-focus-289
https://sgo.broadcastmed.io/p/s/rationale-and-study-design-of-the-kov-hipec-02ra-randomized-multicenter-open-label-phase-iii-trial-of-hyperthermic-intraperitoneal-chemotherapy-in-platinum-resistant-recurrent-ovarian-cancer-290
https://sgo.broadcastmed.io/p/s/vte-prophylaxis-in-gynecologic-cancer-patients-undergoing-chemotherapy-291
https://sgo.broadcastmed.io/p/s/assessment-of-stage-specific-survival-associated-with-uterine-leiomyosarcoma-variants-292
https://sgo.broadcastmed.io/p/s/prevalence-of-germline-likely-pathogenic-or-pathogenic-variants-in-patients-with-endometrial-cancer-diagnosed-at-50-years-within-a-laboratory-based-research-registry-293
https://sgo.broadcastmed.io/p/s/retrospective-analysis-of-lenvatinib-and-pembrolizumab-in-endometrial-cancer-efficacy-by-tumor-characteristic-platinum-status-and-lenvatinib-dose-294
https://sgo.broadcastmed.io/p/s/variants-of-uncertain-significance-vus-are-more-common-in-non-white-populations-undergoing-genetic-testing-for-uterine-cancer-295
https://sgo.broadcastmed.io/p/s/obesity-and-high-risk-histologic-subtypes-of-endometrial-cancer-is-there-a-correlation-296
https://sgo.broadcastmed.io/p/s/surgical-training-in-obgyn-residency-program-director-and-assistant-program-director-perspectives-on-graduating-resident-surgical-competency-297
https://sgo.broadcastmed.io/p/s/national-patterns-in-extent-of-cytoreductive-surgery-and-hospital-outcomes-among-older-patients-with-ovarian-cancer-298
https://sgo.broadcastmed.io/p/s/complement-c3-inhibition-with-pegcetacoplan-controls-malignant-effusions-in-recurrent-ovarian-cancer-interim-results-from-a-phase-2-trial-299
https://sgo.broadcastmed.io/p/s/gynecologic-and-breast-cancer-during-pregnancy-is-associated-with-composite-severe-maternal-morbidity-and-neonatal-morbidity-300
https://sgo.broadcastmed.io/p/s/trends-and-disparities-in-ovarian-preservation-for-early-stage-low-risk-endometrial-cancer-301
https://sgo.broadcastmed.io/p/s/higher-use-of-avoidant-coping-mechanisms-is-associated-with-worse-psychological-well-being-and-financial-toxicity-during-treatment-for-gynecologic-cancer-302
https://sgo.broadcastmed.io/p/s/trends-in-surgical-outcomes-and-overall-survival-among-women-undergoing-debulking-surgery-for-advanced-ovarian-cancer-in-the-us-analysis-of-the-national-cancer-database-303
https://sgo.broadcastmed.io/p/s/compliance-with-the-cervical-cancer-screening-and-diagnostic-follow-up-cascade-prior-to-a-cervical-cancer-diagnosis-a-single-institution-retrospective-cohort-study-304
https://sgo.broadcastmed.io/p/s/ca-125-at-ovarian-cancer-diagnosis-305
https://sgo.broadcastmed.io/p/s/racial-and-ethnic-enrollment-disparities-in-clinical-trials-leading-to-fda-approvals-for-gynecologic-malignancies-306
https://sgo.broadcastmed.io/p/s/rising-rates-of-advanced-stage-cervical-cancer-disproportionate-burden-on-hispanic-women-307
https://sgo.broadcastmed.io/p/s/take-it-or-leave-it-incidental-appendectomy-at-time-of-gynecologic-oncology-laparotomy-308
https://sgo.broadcastmed.io/p/s/pro-platinum-a-randomized-double-blind-placebo-controlled-study-to-investigate-the-efficacy-of-a-probiotic-intervention-on-the-gut-and-vaginal-microbiome-in-ovarian-cancer-patients-undergoing-platinum-309
https://sgo.broadcastmed.io/p/s/assessment-of-gut-microbiome-alterations-on-immunotherapy-response-in-a-cervical-cancer-mouse-model-310
https://sgo.broadcastmed.io/p/s/enrollment-proportions-and-temporal-trends-in-gynecologic-oncology-phase-3-registration-clinical-trials-a-decade-of-disparities-in-review-311
https://sgo.broadcastmed.io/p/s/the-rise-of-electronic-cigarettes-relationship-between-electronic-cigarettes-and-cervical-cancer-312
https://sgo.broadcastmed.io/p/s/impact-of-the-2023-2024-chemotherapy-shortage-on-patient-care-and-outcomes-in-gynecologic-oncology-a-society-of-gynecologic-oncology-survey-313
https://sgo.broadcastmed.io/p/s/factors-associated-with-the-need-for-post-radical-hysterectomy-radiation-in-early-stage-cervical-cancer-measuring-2-4-cm-314
https://sgo.broadcastmed.io/p/s/machine-learning-risk-based-prediction-of-endometrial-cancer-recurrence-315
https://sgo.broadcastmed.io/p/s/shifting-demographics-exploring-racial-and-ethnic-diversity-trends-in-gynecologic-oncology-fellowship-trainees-316
https://sgo.broadcastmed.io/p/s/clinical-efficacy-of-pembrolizumab-and-lenvatinib-monotherapy-and-combination-therapy-in-patients-with-platinum-resistant-high-grade-serous-ovarian-cancer-317
https://sgo.broadcastmed.io/p/s/redefining-holistic-care-for-gynecologic-hereditary-cancer-syndromes-through-universal-social-work-referrals-318
https://sgo.broadcastmed.io/p/s/utility-of-preoperative-imaging-in-endometrial-carcinoma-319
https://sgo.broadcastmed.io/p/s/virtual-versus-reality-assessing-the-accuracy-of-a-digital-cancer-risk-assessment-tool-in-a-gynecologic-oncology-clinic-320
https://sgo.broadcastmed.io/p/s/integrated-analysis-of-clinical-presentation-prognostic-factors-treatment-options-survival-and-genomic-drivers-in-cervical-clear-cell-carcinoma-compared-with-usual-type-adenocarcinoma-321
https://sgo.broadcastmed.io/p/s/epithelial-ovarian-cancer-perpetuates-immunosuppression-by-up-regulating-regulatory-t-cells-and-adenosine-signaling-322
https://sgo.broadcastmed.io/p/s/upregulation-of-klf4-nr4a1-signaling-reduces-parp-inhibitor-induced-apoptosis-in-brca2-mutated-epithelial-ovarian-cancer-cells-323
https://sgo.broadcastmed.io/p/s/clinical-utility-of-additional-imaging-in-clinical-stage-ib2-or-less-cervical-carcinoma-based-on-preoperative-pelvic-mri-324
https://sgo.broadcastmed.io/p/s/development-of-a-novel-nanodiagnostic-activated-by-matrix-metalloproteinase-9-mmp-9-for-early-detection-of-ovarian-cancer-325
https://sgo.broadcastmed.io/p/s/clinicopathologic-features-and-survival-outcomes-in-women-with-uterine-versus-retroperitoneal-leiomyosarcoma-326
https://sgo.broadcastmed.io/p/s/nsc59984-as-a-potent-radiosensitizer-and-cytotoxic-agent-in-tp53-mutated-endometrial-cancer-327
https://sgo.broadcastmed.io/p/s/cost-analysis-associated-with-enhanced-recovery-after-surgery-eras-implementation-among-ovarian-cancer-patients-by-race-and-ethnicity-328
https://sgo.broadcastmed.io/p/s/real-world-outcomes-in-patients-with-epithelial-ovarian-cancer-who-received-first-line-maintenance-niraparib-interim-results-from-the-1nspire-chart-review-study-329
https://sgo.broadcastmed.io/p/s/utility-of-computerized-tomography-in-pre-operative-decision-making-in-women-with-uterine-cancer-330
https://sgo.broadcastmed.io/p/s/assessing-the-relationship-between-kelim-score-and-response-to-first-line-maintenance-niraparib-therapy-in-non-brca-mutant-advanced-ovarian-cancer-331
https://sgo.broadcastmed.io/p/s/impact-of-chemotherapy-provider-specialty-on-outcomes-in-ovarian-cancer-332
https://sgo.broadcastmed.io/p/s/a-multicenter-study-of-laparoscopic-versus-laparotomic-surgery-in-the-treatment-of-stage-i-adult-granulosa-cell-and-sertoli-leydig-cell-tumors-larges-gynecologic-oncology-research-investigators-collab-333
https://sgo.broadcastmed.io/p/s/a-multi-disciplinary-pilot-program-to-prevent-cardiovascular-bone-and-neurologic-disease-among-patients-with-premature-surgical-menopause-334
https://sgo.broadcastmed.io/p/s/mutations-and-minerals-examining-the-impact-of-risk-reducing-surgical-menopause-on-bone-health-335
https://sgo.broadcastmed.io/p/s/cure-after-complete-remission-of-recurrent-ovarian-cancer-a-multicenter-retrospective-study-336
https://sgo.broadcastmed.io/p/s/endometrial-cancer-in-basic-and-translational-science-is-there-a-publication-bias-337
https://sgo.broadcastmed.io/p/s/efbemalenograstim-alfa-for-primary-prophylaxis-of-chemotherapy-induced-neutropenia-in-patients-with-ovarian-and-cervical-cancer-a-single-arm-multicenter-clinical-trial-338
https://sgo.broadcastmed.io/p/s/redefining-cytoreductive-surgery-for-advanced-ovarian-cancer-in-the-neoadjuvant-chemotherapy-era-339
https://sgo.broadcastmed.io/p/s/simple-vs-radical-hysterectomy-for-women-with-early-stage-cervical-cancers-is-it-time-to-shape-up-340
https://sgo.broadcastmed.io/p/s/sequencing-of-mirvetuximab-soravtansine-and-weekly-paclitaxel-does-order-matter-341
https://sgo.broadcastmed.io/p/s/title-contemporary-outcomes-among-gynecologic-oncology-patients-with-malignant-bowel-obstructions-342
https://sgo.broadcastmed.io/p/s/a-phase-1-dose-escalation-study-of-gsk5733584-a-b7-h4-targeted-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors-including-dose-expansion-in-patients-with-endometrial-and-platinum-resista-343
https://sgo.broadcastmed.io/p/s/disparities-in-mri-access-by-insurance-among-cervical-cancer-patients-receiving-chemoradiation-344
https://sgo.broadcastmed.io/p/s/disparities-in-time-to-mri-by-race-and-ethnicity-among-individuals-receiving-chemoradiation-for-treatment-of-cervical-cancer-345
https://sgo.broadcastmed.io/p/s/prognostic-value-of-circulating-tumor-dna-in-endometrial-cancer-a-systematic-review-and-meta-analysis-346
https://sgo.broadcastmed.io/p/s/genetic-ancestry-and-hpv-subtype-distribution-and-novel-integration-sites-in-a-diverse-patient-population-with-cervical-cancer-347
https://sgo.broadcastmed.io/p/s/genetic-ancestry-and-genomic-alterations-of-cervical-cancer-in-a-diverse-patient-population-348
https://sgo.broadcastmed.io/p/s/survival-after-incidental-cervical-cancer-diagnosis-following-simple-hysterectomy-compared-to-planned-oncological-management-in-tumors-equal-2-cm-349
https://sgo.broadcastmed.io/p/s/leveraging-social-media-to-boost-cascade-genetic-testing-engagement-insights-from-the-ignite-tx-study-350
https://sgo.broadcastmed.io/p/s/optimizing-participant-recruitment-strategies-to-increase-cascade-genetic-testing-351
https://sgo.broadcastmed.io/p/s/the-impact-of-minimally-invasive-surgery-on-inflammatory-response-and-postoperative-complications-in-advanced-ovarian-cancer-a-case-control-study-from-the-ultra-lap-trial-352
https://sgo.broadcastmed.io/p/s/gastric-wall-involvement-in-patients-with-advanced-ovarian-cancer-incidence-surgical-management-and-morbidity-353
https://sgo.broadcastmed.io/p/s/differences-in-survival-among-advanced-stage-ovarian-cancer-patients-receiving-systemic-therapy-before-and-after-fda-approval-of-targeted-therapies-354
https://sgo.broadcastmed.io/p/s/impact-of-social-determinants-of-health-on-caregiver-distress-in-gynecologic-oncology-355
https://sgo.broadcastmed.io/p/s/social-determinants-driving-distress-insights-from-patients-undergoing-gynecologic-cancer-treatment-356
https://sgo.broadcastmed.io/p/s/a-phase-3-open-label-randomized-study-of-rinatabart-sesutecan-rina-s-versus-investigators-choice-of-chemotherapy-in-patients-with-platinum-resistant-ovarian-cancer-proc-357
https://sgo.broadcastmed.io/p/s/melfing-out-histopathologic-and-survival-outcomes-in-low-grade-endometrial-cancer-with-microcystic-elongated-fragmented-pattern-of-myometrial-invasion-358
https://sgo.broadcastmed.io/p/s/utilization-of-laparoscopy-prior-to-laparotomy-in-primary-debulking-surgery-for-advanced-epithelial-ovarian-cancer-a-national-cancer-database-analysis-359
https://sgo.broadcastmed.io/p/s/disparities-in-facility-level-adoption-of-minimally-invasive-interval-cytoreductive-surgery-for-advanced-ovarian-cancer-360
https://sgo.broadcastmed.io/p/s/disparities-in-facility-level-adoption-of-sentinel-lymph-node-mapping-for-early-stage-cervical-cancer-361
https://sgo.broadcastmed.io/p/s/can-we-solve-the-small-sample-size-problem-in-ovarian-cancer-using-ai-generated-synthetic-data-362
https://sgo.broadcastmed.io/p/s/the-wee1-inhibitor-azenosertib-shows-synergistic-anti-tumor-effects-with-microtubule-inhibitor-based-antibody-drug-conjugates-adcs-in-preclinical-models-363
https://sgo.broadcastmed.io/p/s/comparative-efficacy-and-safety-of-low-dose-vs-high-dose-bevacizumab-in-ovarian-cancer-a-systematic-literature-review-and-indirect-treatment-comparison-364
https://sgo.broadcastmed.io/p/s/extracellular-vesicles-derived-from-vaginal-bacteria-initiate-the-progression-of-early-phase-ovarian-carcinoma-at-fallopian-tubes-365
https://sgo.broadcastmed.io/p/s/hyperthermia-induced-sensitization-of-platinum-resistant-ovarian-cancer-cells-a-potential-strategy-for-overcoming-drug-resistance-366
https://sgo.broadcastmed.io/p/s/comparative-analysis-of-open-vs-closed-hipec-techniques-in-the-treatment-of-advanced-ovarian-cancer-a-retrospective-multicenter-study-kgog-3042-ancillary-study-367
https://sgo.broadcastmed.io/p/s/patient-derived-organoids-how-can-we-continue-to-personalize-treatment-for-ovarian-cancer-patients-368
https://sgo.broadcastmed.io/p/s/single-arm-phase-ii-study-of-carboplatin-and-mirvetuximab-soravtansine-in-first-line-treatment-of-patients-receiving-neoadjuvant-chemotherapy-with-advanced-stage-ovarian-fallopian-tube-or-primary-peri-369
https://sgo.broadcastmed.io/p/s/monitoring-disease-progression-using-human-papillomavirus-ctdna-in-hpv-1618-associated-cervical-squamous-cell-carcinoma-and-adenocarcinoma-370
https://sgo.broadcastmed.io/p/s/utility-of-preoperative-imaging-in-endometrial-cancer-to-assess-the-presence-of-lymph-node-metastases-371
https://sgo.broadcastmed.io/p/s/part-c-of-a-phase-12-study-evaluating-single-agent-rinatabart-sesutecan-rina-s-in-patients-with-advanced-andor-metastatic-platinum-resistant-ovarian-cancer-proc-372
https://sgo.broadcastmed.io/p/s/how-to-rural-endometrial-cancer-patients-perceive-diet-and-exercise-373
https://sgo.broadcastmed.io/p/s/comparison-of-breast-and-gastric-her2-immunohistochemistry-ihc-scoring-criteria-in-the-assessment-of-endometrial-endometrioid-adenocarcinoma-eea-374
https://sgo.broadcastmed.io/p/s/risk-of-residual-invasive-disease-after-conization-in-patients-with-cervical-cancer-375
https://sgo.broadcastmed.io/p/s/prognostic-factors-impacting-survival-in-patients-undergoing-hyperthermic-intraperitoneal-chemotherapy-hipec-for-high-grade-ovarian-cancer-376
https://sgo.broadcastmed.io/p/s/the-impact-of-neoadjuvant-chemotherapy-on-surgical-debulking-and-gross-residual-disease-in-epithelial-ovarian-cancer-377
https://sgo.broadcastmed.io/p/s/delay-in-chemotherapy-initiation-post-op-negatively-impacts-outcomes-in-patients-with-endometrial-cancer-378
https://sgo.broadcastmed.io/p/s/the-impact-of-covid19-on-surgical-delays-in-endometrial-cancer-treatment-379
https://sgo.broadcastmed.io/p/s/impact-of-primary-language-on-symptom-reporting-and-experience-with-symptom-assessment-tools-in-english-and-spanish-speaking-gynecology-oncology-patients-380
https://sgo.broadcastmed.io/p/s/comparison-of-scar-assessment-between-laparo-endoscopic-single-site-and-conventional-laparoscopic-surgery-for-early-stage-endometrial-cancer-a-randomized-controlled-trial-381
https://sgo.broadcastmed.io/p/s/consecutive-negative-screening-tests-for-ovarian-cancer-a-reliable-basis-for-reassurance-382
https://sgo.broadcastmed.io/p/s/management-of-epithelial-and-placental-site-trophoblastic-tumors-in-the-united-states-a-national-cancer-database-study-383
https://sgo.broadcastmed.io/p/s/the-role-of-digital-inequities-and-uterine-cancer-treatment-and-survival-disparities-384
https://sgo.broadcastmed.io/p/s/impact-of-isolated-tumor-cells-in-early-staged-surgically-treated-cervical-cancer-canadian-cervical-cancer-collaborative4c-study-385
https://sgo.broadcastmed.io/p/s/decreasing-surgical-site-infection-rates-in-gynecologic-oncology-patients-with-the-addition-of-metronidazole-to-cefazolin-386
https://sgo.broadcastmed.io/p/s/predictive-value-of-preoperative-laboratory-values-and-clinical-factors-for-postoperative-complications-in-cervical-cancer-surgery-a-nsqip-analysis-2014-2022-387
https://sgo.broadcastmed.io/p/s/preoperative-and-intraoperative-predictors-of-postoperative-myocardial-infarction-in-gynecologic-oncology-surgeries-388
https://sgo.broadcastmed.io/p/s/multi-node-pi3kaktmtor-pathway-inhibition-with-sapanisertib-and-serabelisib-achieves-superior-efficacy-in-endometrial-cancer-models-versus-single-node-inhibitors-389
https://sgo.broadcastmed.io/p/s/the-role-of-platinum-free-interval-in-recurrent-ovarian-cancer-patients-undergoing-secondary-cytoreductive-surgery-and-hyperthemic-intraperitoneal-chemotherapy-390
https://sgo.broadcastmed.io/p/s/higher-rates-of-her2-ihc-2-plus-ish-amplification-detected-by-institutional-her2-testing-in-patients-with-endometrial-cancer-391
https://sgo.broadcastmed.io/p/s/sentinel-lymph-node-mapping-in-women-with-endometrial-cancer-with-a-preoperative-diagnosis-of-complex-atypical-endometrial-hyperplasia-392
https://sgo.broadcastmed.io/p/s/qualitative-patient-and-provider-perspectives-centering-patients-needs-for-improved-navigation-in-cervical-cancer-393
https://sgo.broadcastmed.io/p/s/identification-of-tumor-marker-ganglioside-signatures-in-serum-for-detection-of-ovarian-cancer-394
https://sgo.broadcastmed.io/p/s/vnotes-as-a-surgical-alternative-in-the-management-of-endometrial-cancer-a-systematic-review-and-meta-analysis-395
https://sgo.broadcastmed.io/p/s/single-port-versus-conventional-minimally-invasive-surgery-in-early-stage-endometrial-cancer-a-systematic-review-and-meta-analysis-396
https://sgo.broadcastmed.io/p/s/development-and-validation-of-a-radiomics-nomogram-for-metastasis-prediction-in-neuroendocrine-carcinoma-of-the-cervix-397
https://sgo.broadcastmed.io/p/s/near-far-care-wherever-they-are-same-day-discharges-for-minimally-invasive-hysterectomies-by-gynecologic-oncologists-in-a-rural-population-a-single-institution-retrospective-study-398
https://sgo.broadcastmed.io/p/s/improvements-and-disparities-in-survival-for-high-grade-serous-ovarian-cancer-a-contemporary-assessment-of-real-world-patients-399
https://sgo.broadcastmed.io/p/s/linking-human-papillomavirus-infections-to-cervical-cancer-driver-mutations-and-survival-400
https://sgo.broadcastmed.io/p/s/herv-k-env-monoclonal-antibody-discovery-and-structural-identification-uncovering-viral-epitopes-in-ovarian-cancer-401
https://sgo.broadcastmed.io/p/s/racial-disparities-in-financial-toxicity-and-social-risks-among-urban-endometrial-cancer-survivors-402
https://sgo.broadcastmed.io/p/s/docosahexaenoic-acid-dha-exhibits-anti-tumorigenic-and-anti-inflammatory-effects-and-has-synergy-with-paclitaxel-in-endometrial-cancer-403
https://sgo.broadcastmed.io/p/s/inter-relationship-of-race-the-microbiome-and-the-metabolome-in-endometrial-cancer-404
https://sgo.broadcastmed.io/p/s/trends-in-fda-approval-of-novel-therapies-in-womens-cancer-a-study-of-the-last-25-years-405
https://sgo.broadcastmed.io/p/s/value-based-integrated-recommendation-software-guiding-ovarian-cancer-treatment-virgo2-trial-of-patient-reported-outcome-measure-prom-based-recommendation-program-to-improve-health-related-qualit-406
https://sgo.broadcastmed.io/p/s/efficacy-and-feasibility-of-pre-operative-high-intensity-interval-training-in-endometrial-cancer-patients-407
https://sgo.broadcastmed.io/p/s/a-phase-2-study-of-niraparib-plus-bevacizumab-maintenance-following-front-line-1l-platinum-based-chemotherapy-ct-with-bevacizumab-bev-in-advanced-ovarian-cancer-aoc-final-analysis-from-the-ovario-stud-408
https://sgo.broadcastmed.io/p/s/current-state-of-family-planning-and-parental-leave-in-obgyn-fellowships-409
https://sgo.broadcastmed.io/p/s/distance-to-treatment-of-locally-advanced-cervical-cancer-on-the-gulf-coast-in-a-post-covid-era-does-it-affect-adherence-to-guideline-concordant-therapy-410
https://sgo.broadcastmed.io/p/s/does-the-law-reflect-patient-preferences-discordance-between-legal-surrogate-hierarchy-and-chosen-surrogate-decision-makers-in-preoperative-patients-411
https://sgo.broadcastmed.io/p/s/assessing-pre-test-genetic-syndrome-knowledge-and-readiness-to-share-with-relatives-among-participants-in-a-community-based-randomized-controlled-trial-investigating-means-to-increase-cascade-genetic--412
https://sgo.broadcastmed.io/p/s/malignancy-related-ureteral-obstruction-in-gynecologic-cancer-success-of-initial-mechanical-interventions-413
https://sgo.broadcastmed.io/p/s/does-the-outcome-match-the-intent-cancer-directed-treatments-after-intervention-for-malignancy-related-ureteral-obstruction-in-gynecologic-cancer-414
https://sgo.broadcastmed.io/p/s/the-impact-of-socioeconomic-disparities-on-endometrial-cancer-survival-an-analysis-of-the-index-of-concentration-at-the-extremes-415
https://sgo.broadcastmed.io/p/s/agreement-across-assays-for-detection-of-homologous-recombination-deficiency-hrd-biomarkers-including-a-scar-based-signature-hrdsig-and-genomic-instability-score-gis-416
https://sgo.broadcastmed.io/p/s/identifying-and-breaking-barriers-for-the-treatment-of-gynecologic-malignancies-within-the-lgbtqia-plus-community-417
https://sgo.broadcastmed.io/p/s/rare-ovarian-adenocarcinomas-exhibit-a-distinct-germline-landscape-418
https://sgo.broadcastmed.io/p/s/the-roles-of-gynecology-oncologists-in-pelvic-exenteration-for-colorectal-cancer-419
https://sgo.broadcastmed.io/p/s/addressing-dynamic-physical-changes-during-neoadjuvant-chemotherapy-in-ovarian-cancer-patients-through-prehabilitation-implementation-420
https://sgo.broadcastmed.io/p/s/cervical-cancer-2010-2019-south-dakota-catchment-of-40000-square-miles-421
https://sgo.broadcastmed.io/p/s/tumor-suppressive-microenvironment-in-ovarian-cancer-ascites-422
https://sgo.broadcastmed.io/p/s/predictive-value-of-primary-tumor-suvmax-on-18f-fluro-2-deoxy-d-glucose-positron-emission-tomography-and-computed-tomography-in-patients-undergoing-fertility-sparing-treatment-for-early-endometrial-ca-423
https://sgo.broadcastmed.io/p/s/equitable-preoperative-biopsy-cancer-detection-and-surgical-management-by-race-and-social-vulnerability-index-in-endometrial-cancer-patients-424
https://sgo.broadcastmed.io/p/s/dynamic-role-of-circulating-immune-cells-in-the-progression-of-cervical-malignant-lesion-a-two-sample-mendelian-randomization-study-425
https://sgo.broadcastmed.io/p/s/lipids-as-fundamental-components-of-cells-exert-a-substantial-influence-on-diverse-biological-processes-although-significant-their-precise-impact-on-cervical-cancer-development-remains-largely-uncerta-426
https://sgo.broadcastmed.io/p/s/a-novel-deep-learning-model-for-automatic-segmentation-in-cervical-cancer-brachytherapy-427
https://sgo.broadcastmed.io/p/s/nituzumab-plus-serplulimab-combined-with-sbrt-in-recurrent-advanced-cervical-cancer-a-prospective-multicenter-single-arm-phase-ii-clinical-428
https://sgo.broadcastmed.io/p/s/comparison-of-long-term-clinical-outcomes-between-patients-with-and-without-neoadjuvant-therapy-before-surgery-in-stage-ib2-iib-cervical-cancer-a-propensity-score-matched-study-429
https://sgo.broadcastmed.io/p/s/the-impact-of-the-covid-19-pandemic-on-the-diagnosis-treatment-and-prognosis-of-ovarian-cancer-in-the-united-statesa-retrospective-cohort-study-based-on-the-seer-database-430
https://sgo.broadcastmed.io/p/s/human-papillomavirus-hpv-vaccination-rates-among-asian-american-and-pacific-islander-aapi-patients-431
https://sgo.broadcastmed.io/p/s/analysis-of-adjuvant-chemotherapy-for-endometrial-cancer-in-patients-with-intermediate-risk-factors-432
https://sgo.broadcastmed.io/p/s/efficacy-and-safety-of-pembrolizumab-in-combination-with-olaparib-in-previously-treated-recurrent-cervical-cancer-a-open-label-single-arm-phase-2-study-433
https://sgo.broadcastmed.io/p/s/ovarian-low-and-high-grade-serous-carcinoma-as-a-synchronous-or-metachronous-phenomenon-a-cohort-of-30-cases-434
https://sgo.broadcastmed.io/p/s/molecular-classification-and-nodal-metastases-in-endometrial-cancer-patients-testing-prediction-potential-435
https://sgo.broadcastmed.io/p/s/phase-1-dose-escalation-of-artemicoffee-in-women-with-advanced-ovarian-cancer-436
https://sgo.broadcastmed.io/p/s/trends-in-immune-related-adverse-events-among-patients-with-endometrial-carcinoma-437
https://sgo.broadcastmed.io/p/s/survival-outcomes-of-low-grade-serous-ovarian-cancer-the-significance-of-hormone-receptor-positivity-438
https://sgo.broadcastmed.io/p/s/cervical-dysplasia-and-follow-up-patterns-among-the-incarcerated-women-in-oklahoma-439
https://sgo.broadcastmed.io/p/s/in-vitro-and-in-vivo-activity-of-datopotamab-deruxtecan-an-antibody-drug-conjugate-directed-to-trophoblast-cell-surface-antigen-2-trop2-in-uterine-and-ovarian-carcinosarcoma-440
https://sgo.broadcastmed.io/p/s/exploring-the-association-of-body-mass-index-and-length-of-stay-in-hospital-of-patients-undergoing-minimally-invasive-surgery-for-uterine-cancer-a-national-surgical-quality-improvement-program-nsqip-s-441
https://sgo.broadcastmed.io/p/s/the-rising-incidence-of-advanced-stage-cervical-cancer-in-the-post-pandemic-era-442
https://sgo.broadcastmed.io/p/s/ineffective-nonsense-mediated-decay-is-common-in-high-grade-serous-ovarian-cancer-and-may-represent-an-unappreciated-driver-of-tumor-behavior-443
https://sgo.broadcastmed.io/p/s/high-rates-of-venous-thromboembolism-in-endometrial-cancer-patients-on-systemic-therapy-an-opportunity-for-risk-assessment-and-intervention-444
https://sgo.broadcastmed.io/p/s/evolutionary-experimentation-highlights-novel-collateral-sensitivity-to-etoposide-in-platinum-resistant-endometrial-cancer-445
https://sgo.broadcastmed.io/p/s/genomic-analysis-of-environmental-and-drug-targets-associated-with-mismatch-repair-status-in-endometrial-cancer-446
https://sgo.broadcastmed.io/p/s/identification-of-quorum-sensing-molecules-in-endometrial-cancer-exploring-the-role-of-complex-vaginal-microbiome-interactions-as-a-risk-biomarker-447
https://sgo.broadcastmed.io/p/s/altered-expression-and-localization-of-ccn3-in-endometrial-cancer-448
https://sgo.broadcastmed.io/p/s/the-impact-of-germline-mutations-in-patients-with-ovarian-carcinosarcoma-449
https://sgo.broadcastmed.io/p/s/unmet-needs-in-ovarian-cancer-treatments-perspectives-from-patients-caregivers-and-oncologists-450
https://sgo.broadcastmed.io/p/s/evaluating-the-prognostic-role-of-lymphovascular-space-invasion-in-figo-2009-stage-i-endometrioid-endometrial-cancer-according-to-depth-of-myoinvasion-451
https://sgo.broadcastmed.io/p/s/machine-learning-algorithms-for-risk-stratification-in-cervical-cancer-screening-tests-among-the-ascuslsil-population-evidence-from-the-korean-hpv-cohort-study-452
https://sgo.broadcastmed.io/p/s/relationship-between-preoperative-neutropenia-and-incidence-of-infectious-complications-after-interval-debulking-surgery-for-advanced-epithelial-ovarian-cancer-453
https://sgo.broadcastmed.io/p/s/optimizing-end-of-life-care-in-elderly-ovarian-cancer-patients-what-can-we-do-better-454
https://sgo.broadcastmed.io/p/s/current-clinical-trial-screening-practices-in-gynecologic-oncology-455
https://sgo.broadcastmed.io/p/s/area-level-socioeconomic-disadvantage-is-associated-with-postoperative-complications-following-gynecologic-cancer-surgery-456
https://sgo.broadcastmed.io/p/s/race-and-ethnicity-are-associated-with-different-survival-outcomes-in-endometrial-cancer-patients-with-high-grade-histologic-subtypes-457
https://sgo.broadcastmed.io/p/s/non-hispanic-black-woman-with-uterine-carcinosarcoma-have-worse-survival-outcomes-regardless-of-stage-at-presentation-458
https://sgo.broadcastmed.io/p/s/preclinical-efficacy-of-the-estrogen-receptor-degrader-fulvestrant-in-combination-with-rafmek-clamp-avutometinib-and-fak-inhibitor-in-low-grade-serous-ovarian-cancer-with-acquired-resistance-to-chemot-459
https://sgo.broadcastmed.io/p/s/outcomes-of-fertility-sparing-treatment-in-a-case-series-of-patients-with-lynch-syndrome-460
https://sgo.broadcastmed.io/p/s/contemporary-survivorship-challenges-among-diverse-endometrial-cancer-patients-findings-from-the-promote-study-patient-reported-outcomes-measurement-opportunities-through-equity-461
https://sgo.broadcastmed.io/p/s/sentinel-lymph-node-mapping-versus-systemic-lymphadenectomy-in-high-risk-endometrial-cancer-patients-a-meta-analysis-of-oncologic-outcomes-462
https://sgo.broadcastmed.io/p/s/should-i-take-a-parp-inhibitor-as-maintenance-therapy-for-advanced-ovarian-cancer-development-of-patient-decision-aid-463
https://sgo.broadcastmed.io/p/s/multimodal-models-of-hgsc-chemo-response-prediction-with-integration-of-deep-learning-models-of-imaging-and-genomic-data-464
https://sgo.broadcastmed.io/p/s/alter-go-010-a-multicenter-single-arm-phase-2-study-of-anlotinib-combined-with-carboplatin-plus-paclitaxel-and-maintenance-anlotinib-as-front-line-treatment-for-newly-diagnosed-advanced-ovarian-cancer-465
https://sgo.broadcastmed.io/p/s/demographics-in-pulmonary-metastasis-from-endometrial-cancer-an-ncdb-review-466
https://sgo.broadcastmed.io/p/s/effect-of-staging-modalities-on-treatment-recommendations-and-time-to-treatment-in-cervical-cancer-467
https://sgo.broadcastmed.io/p/s/the-relationship-between-pole-mutant-status-and-microsatellite-instability-in-endometrial-cancer-468
https://sgo.broadcastmed.io/p/s/figo-2023-stage-iiic-endometrial-cancer-survival-assessment-per-metastatic-size-and-anatomical-location-469
https://sgo.broadcastmed.io/p/s/tranexamic-acid-use-in-advanced-ovarian-cancer-patients-undergoing-cytoreductive-surgery-quality-improvement-study-470
https://sgo.broadcastmed.io/p/s/the-impact-of-uterine-fibroids-and-non-endometrioid-histology-on-the-performance-of-transvaginal-ultrasound-for-the-detection-of-endometrial-cancer-471
https://sgo.broadcastmed.io/p/s/clear-cell-carcinoma-of-cervix-and-vagina-a-review-of-63-cases-in-the-post-des-era-472
https://sgo.broadcastmed.io/p/s/geographic-and-socioeconomic-factors-associated-with-hyperthermic-intraperitoneal-chemotherapy-use-in-advanced-ovarian-cancer-a-national-cancer-database-study-473
https://sgo.broadcastmed.io/p/s/targeting-lipa-as-a-therapeutic-strategy-in-endometrial-carcinoma-via-induction-of-endoplasmic-reticulum-stress-474
https://sgo.broadcastmed.io/p/s/assessing-the-impact-of-the-covid-19-pandemic-on-the-diagnosis-and-staging-of-gynecologic-cancers-using-the-seer-database-475
https://sgo.broadcastmed.io/p/s/ovarian-adnexal-reporting-and-data-system-o-rads-for-adnexal-masses-are-we-hitting-the-mark-476
https://sgo.broadcastmed.io/p/s/cervical-cancer-will-be-a-rare-disease-in-ten-years-whats-our-role-477
https://sgo.broadcastmed.io/p/s/harnessing-public-excitement-can-this-drive-clinical-trial-participation-for-breakthrough-therapies-478
https://sgo.broadcastmed.io/p/s/evaluating-patients-understanding-of-their-gynecologic-cancer-a-cross-sectional-survey-study-assessing-an-etiology-for-disparities-in-clinical-trial-enrollment-479
https://sgo.broadcastmed.io/p/s/development-of-a-microphysiologic-system-for-ovarian-cancer-the-vascularized-microtumor-480
https://sgo.broadcastmed.io/p/s/non-canonical-notch-signaling-and-gamma-secretase-inhibitors-as-a-potential-mechanisms-to-overcome-immunotherapy-resistance-481
https://sgo.broadcastmed.io/p/s/patients-with-incurable-gynecologic-malignancies-spend-significant-time-receiving-healthcare-in-the-last-six-months-of-life-482
https://sgo.broadcastmed.io/p/s/is-hpv-going-viral-comparison-of-quality-and-impact-of-hpv-vaccine-media-depiction-in-english-and-spanish-483
https://sgo.broadcastmed.io/p/s/real-world-experience-of-treating-ovarian-cancer-with-parp-inhibitors-484
https://sgo.broadcastmed.io/p/s/assessing-for-differences-in-endometrial-cancer-tumor-genomic-profile-between-latinxhispanic-patients-and-non-hispanic-white-patients-485
https://sgo.broadcastmed.io/p/s/identifying-extracellular-vesicle-based-biomarkers-that-distinguish-responders-from-non-responders-in-endobarr-clinical-trial-patients-486
https://sgo.broadcastmed.io/p/s/the-reel-deal-assessing-the-quality-of-medical-information-on-instagram-and-tiktok-reels-for-gynecologic-cancers-487
https://sgo.broadcastmed.io/p/s/conventional-prophylactic-regimen-of-oral-dexamethasone-versus-short-course-intravenous-dexamethasone-to-prevent-paclitaxel-related-hypersensitivity-reactions-in-gynecologic-oncology-patients-489
https://sgo.broadcastmed.io/p/s/hormone-replacement-therapy-improves-clinical-outcomes-in-women-with-iatrogenic-menopause-secondary-to-cervical-cancer-treatment-490
https://sgo.broadcastmed.io/p/s/associations-between-area-level-digital-inequities-and-cervical-cancer-treatment-and-outcomes-491
https://sgo.broadcastmed.io/p/s/patient-perspectives-on-palliative-care-in-gynecologic-oncology-492
https://sgo.broadcastmed.io/p/s/the-international-gynecologic-cancer-society-igcs-global-fellowship-program-updates-in-advancing-access-to-gynecologic-oncology-care-globally-493
https://sgo.broadcastmed.io/p/s/opportunistic-salpingectomy-at-the-time-of-hysterectomy-influence-of-patient-sharing-among-physicians-494
https://sgo.broadcastmed.io/p/s/undifferentiated-ovarian-carcinoma-a-decade-long-cohort-study-reveals-stable-incidence-and-critical-prognostic-factors-495
https://sgo.broadcastmed.io/p/s/molecular-testing-in-the-upfront-setting-for-high-grade-endometrial-cancers-how-are-we-doing-496
https://sgo.broadcastmed.io/p/s/multimodal-models-of-endometrial-cancer-recurrence-prediction-with-integration-of-deep-learning-models-of-histopathology-and-genomic-data-497
https://sgo.broadcastmed.io/p/s/prediction-of-endometrial-cancer-recurrence-with-deep-learning-analysis-of-histopathology-slides-498
https://sgo.broadcastmed.io/p/s/should-we-individualize-cervical-cancer-screening-recommendations-an-assessment-of-the-clinical-utility-of-traditional-cervical-cancer-screening-methods-in-transmasculine-patients-499
https://sgo.broadcastmed.io/p/s/management-of-significant-pleural-effusion-at-first-ovarian-cancer-consultation-outcomes-of-whole-cohort-triage-to-neoadjuvant-chemotherapy-without-thoracic-debulking-2016-2021-500
https://sgo.broadcastmed.io/p/s/kmt2c-and-kmt2d-regulate-homologous-recombination-repair-and-parp-inhibitor-sensitivity-in-epithelial-ovarian-cancer-501
https://sgo.broadcastmed.io/p/s/the-neutrophil-albumin-index-as-a-discriminative-tool-for-distinguishing-uterine-leiomyosarcoma-from-uterine-leiomyoma-502
https://sgo.broadcastmed.io/p/s/anrkd22-is-a-novel-prognostic-marker-of-squamous-cell-carcinoma-of-the-uterine-cervix-503
https://sgo.broadcastmed.io/p/s/representation-in-clinical-trials-for-he4-as-a-biomarker-for-ovarian-malignancy-risk-a-review-504
https://sgo.broadcastmed.io/p/s/investigating-the-role-of-the-parp-enzyme-family-in-cervical-cancer-pathogenesis-505
https://sgo.broadcastmed.io/p/s/follow-up-care-of-patients-with-complex-adnexal-masses-in-an-academic-health-system-a-cohort-study-506
https://sgo.broadcastmed.io/p/s/the-effect-of-maintenance-bevacizumab-cycle-length-on-patient-outcomes-and-healthcare-cost-507
https://sgo.broadcastmed.io/p/s/real-world-clinical-management-of-decreased-platelet-counts-in-patients-with-epithelial-ovarian-cancer-who-received-first-line-maintenance-niraparib-in-the-activ1ze-study-508
https://sgo.broadcastmed.io/p/s/applying-social-vulnerability-index-to-examine-local-social-disparities-in-patients-receiving-hysterectomy-509
https://sgo.broadcastmed.io/p/s/lights-genes-action-video-strategies-for-brca12-patient-education-510
https://sgo.broadcastmed.io/p/s/disparities-in-the-utilization-of-hyperthermic-intraperitoneal-chemotherapy-for-patients-with-high-grade-ovarian-cancer-from-2007-2020-511
https://sgo.broadcastmed.io/p/s/characterizing-insurance-access-to-gynecologic-oncology-care-in-california-512
https://sgo.broadcastmed.io/p/s/prophylactic-antibiotic-use-in-vulvar-surgery-513
https://sgo.broadcastmed.io/p/s/where-you-live-matters-geographic-disparities-in-time-to-chemoradiation-initiation-for-cervical-cancer-patients-by-zip-code-514
https://sgo.broadcastmed.io/p/s/to-remove-or-not-to-remove-the-foley-perioperative-outcomes-with-immediate-or-delayed-urinary-catheter-removal-following-minimally-invasive-hysterectomy-515
https://sgo.broadcastmed.io/p/s/the-impact-of-human-papillomavirus-vaccination-on-the-rising-rate-of-vulvar-cancer-incidence-among-women-in-the-united-states-516
https://sgo.broadcastmed.io/p/s/the-effect-of-polyallergy-on-ancillary-service-use-among-postoperative-patients-with-gynecologic-malignancies-517
https://sgo.broadcastmed.io/p/s/us-real-world-biomarker-testing-differences-and-treatment-choice-in-advanced-ovarian-cancer-518
https://sgo.broadcastmed.io/p/s/physician-replace-thyself-can-generative-ai-locate-and-evaluate-ovarian-cancer-genetic-information-519
https://sgo.broadcastmed.io/p/s/incidence-and-timing-of-venous-thromboembolism-in-patients-with-advanced-endometrial-cancer-520
https://sgo.broadcastmed.io/p/s/clinicopathologic-features-and-outcomes-of-ovarian-mucinous-borderline-tumor-with-intraepithelial-carcinoma-521
https://sgo.broadcastmed.io/p/s/perioperative-outcomes-of-heated-intraperitoneal-chemotherapy-hipec-for-patients-enrolled-in-the-feasibility-phase-of-a-randomized-controlled-trial-laparoscopic-cytoreduction-after-neoadjuvant-chemoth-522
https://sgo.broadcastmed.io/p/s/perceived-vs-actual-compliance-after-implementing-a-surgical-site-infection-prevention-bundle-in-gynecologic-surgery-523
https://sgo.broadcastmed.io/p/s/incidence-of-endometrial-cancer-by-preoperative-sampling-method-in-endometrial-intraepithelial-neoplasia-and-impact-on-surgical-management-524
https://sgo.broadcastmed.io/p/s/effectiveness-of-bevacizumab-combination-therapy-in-advanced-cervical-cancer-a-nationwide-real-world-study-525
https://sgo.broadcastmed.io/p/s/braving-the-heat-hipec-outcomes-in-primary-and-interval-debulking-surgery-for-figo-stage-iv-ovarian-cancer-526
https://sgo.broadcastmed.io/p/s/impact-of-covid-19-on-the-timing-of-surgery-for-endometrial-cancer-527
https://sgo.broadcastmed.io/p/s/an-evaluation-of-factors-leading-to-survival-benefit-in-patients-with-advanced-endometrial-cancer-treated-with-combination-therapy-of-pembrolizumab-plus-lenvatinib-528
https://sgo.broadcastmed.io/p/s/assessing-patient-satisfaction-in-same-day-discharge-following-robotic-gynecologic-surgery-529
https://sgo.broadcastmed.io/p/s/demographics-and-inclusion-in-ovarian-cancer-screening-studies-a-review-530
https://sgo.broadcastmed.io/p/s/before-and-after-the-lacc-trial-trends-in-radical-hysterectomies-at-academic-and-non-academic-institutions-531
https://sgo.broadcastmed.io/p/s/inclusion-of-immunohistochemistry-markers-in-a-predictive-model-of-concurrent-endometrioid-endometrial-carcinoma-at-time-of-hysterectomy-for-endometrial-intraepithelial-neoplasiacomplex-atypical-hyper-532
https://sgo.broadcastmed.io/p/s/disparities-in-emergency-department-utilization-among-patients-diagnosed-with-endometrial-cancer-533
https://sgo.broadcastmed.io/p/s/use-of-mirvetuximab-soravtansine-gynx-in-combination-with-bevacizumab-is-associated-with-a-higher-progression-free-survival-534
https://sgo.broadcastmed.io/p/s/laparoscopic-pelvic-lymph-node-dissection-plus-open-abdominal-radical-hysterectomy-in-patients-with-gastric-type-endocervical-adenocarcinoma-535
https://sgo.broadcastmed.io/p/s/a-phase-1-first-in-human-dose-escalation-and-expansion-study-to-evaluate-the-safety-and-tolerability-of-xmab541-claudin-6-x-cd3-t-cell-engaging-bispecific-antibody-in-advanced-solid-tumors-536
https://sgo.broadcastmed.io/p/s/adherence-to-risk-reducing-bilateral-salpingo-oophorectomy-in-carriers-of-a-brca-pathogenic-variant-537
https://sgo.broadcastmed.io/p/s/palliative-care-perceptions-in-advanced-ovarian-cancer-and-first-recurrence-of-gynecological-cancer-patients-a-mixed-methods-study-538
https://sgo.broadcastmed.io/p/s/perspectives-regarding-adult-hpv-vaccination-a-qualitative-study-among-obgyn-practitioners-539
https://sgo.broadcastmed.io/p/s/trends-in-overall-survival-for-patients-diagnosed-with-vulvar-cancer-during-the-covid-19-pandemic-540
https://sgo.broadcastmed.io/p/s/association-between-primary-payor-status-and-palliative-care-utilization-in-advanced-gynecologic-malignancy-541
https://sgo.broadcastmed.io/p/s/survival-in-stage-i-iv-cervical-squamous-cell-carcinoma-adenocarcinoma-or-adenosquamous-carcinoma-542
https://sgo.broadcastmed.io/p/s/ask-questions-in-gynecologic-oncology-asq-gyo-a-randomized-controlled-trial-of-a-question-prompt-list-communication-intervention-in-outpatient-gynecologic-oncology-clinics-543
https://sgo.broadcastmed.io/p/s/face-to-face-vs-screen-to-screen-gynecologic-oncology-fellowship-interview-applicant-perspectives-on-interview-format-544
https://sgo.broadcastmed.io/p/s/implementation-of-figo-2023-staging-may-result-in-overtreatment-of-early-stage-endometrial-cancer-545
https://sgo.broadcastmed.io/p/s/adapting-to-a-new-era-the-shape-trial-and-the-potential-effect-on-surgical-practice-and-fellow-education-in-cervical-cancer-546
https://sgo.broadcastmed.io/p/s/validation-of-2023-figo-stage-ia1-iiic2-endometrial-carcinoma-a-retrospective-analysis-of-two-tertiary-centers-in-south-korea-and-taiwan-547
https://sgo.broadcastmed.io/p/s/combinatorial-platinum-taxane-based-chemotherapy-and-amphiregulin-blockade-significantly-promotes-tumor-regression-in-a-high-grade-serous-ovarian-cancer-immunocompetent-murine-model-548
https://sgo.broadcastmed.io/p/s/evaluation-of-actrii-fc-in-syngeneic-models-of-ovarian-cancer-549
https://sgo.broadcastmed.io/p/s/int-151-effects-on-t-cell-populations-in-ovarian-cancer-exploring-immune-dynamics-in-a-pre-clinical-model-550
https://sgo.broadcastmed.io/p/s/a-tri-specific-killer-engager-trike-targeting-pd-l1-enhances-nk-cell-immune-function-against-ovarian-cancer-551
https://sgo.broadcastmed.io/p/s/feedback-activation-of-mapk-erk12-signaling-causes-resistance-to-trastuzumab-deruxtecan-in-endometrial-cancers-552
https://sgo.broadcastmed.io/p/s/in-vivo-chemotherapy-exposure-alters-expression-of-stemness-and-epithelial-mesenchymal-transition-factors-in-high-grade-serous-ovarian-cancer-samples-553
https://sgo.broadcastmed.io/p/s/quantitative-proteomic-analyses-of-the-tumor-microenvironment-in-cervical-adenocarcinomas-by-silva-pattern-554
https://sgo.broadcastmed.io/p/s/fertility-sparing-treatment-for-atypical-polypoid-adenomyoma-555
https://sgo.broadcastmed.io/p/s/the-high-stakes-of-substance-use-worse-prognosis-and-outcomes-in-cervical-cancer-556
https://sgo.broadcastmed.io/p/s/adjuvant-chemo-radiotherapy-versus-radiotherapy-alone-for-patients-with-intermediate-risk-cervical-cancer-557
https://sgo.broadcastmed.io/p/s/trends-in-overall-survival-for-patients-diagnosed-with-cervical-cancer-during-the-covid-19-pandemic-558
https://sgo.broadcastmed.io/p/s/prior-to-fda-approval-of-pembrolizumab-use-of-immunotherapy-for-primary-treatment-of-advanced-cervical-cancer-was-frequent-and-unequally-distributed-a-national-cancer-database-study-2014-2021-559
https://sgo.broadcastmed.io/p/s/adjuvant-chemotherapy-does-not-appear-to-improve-survival-in-patients-with-2009-figo-stage-i-uterine-serous-carcinoma-without-myoinvasion-560
https://sgo.broadcastmed.io/p/s/modifiable-disparities-in-guideline-concordant-chemotherapy-in-ovarian-cancer-a-national-cancer-database-study-561
https://sgo.broadcastmed.io/p/s/improved-overall-survival-with-combined-chemotherapy-and-radiation-in-stage-i-uterine-carcinosarcoma-a-national-cancer-database-study-562
https://sgo.broadcastmed.io/p/s/cytology-negative-non-myoinvasive-stage-ic-serous-and-clear-cell-endometrial-cancer-assessment-of-adjuvant-therapy-de-escalation-563
https://sgo.broadcastmed.io/p/s/a-phase-ii-study-of-pembrolizumab-monotherapy-in-recurrent-ovarian-cancer-of-the-immunoreactive-subtype-determined-by-nanostring-protype-gene-expression-profiling-564
https://sgo.broadcastmed.io/p/s/an-open-label-phase-ii-study-of-the-efficacy-and-safety-of-abemaciclib-a-cdk46-inhibitor-combined-with-hormonal-therapy-in-selected-patients-with-recurrent-ovarian-or-endometrial-cancer-565
https://sgo.broadcastmed.io/p/s/efficacy-and-safety-of-carboplatinpaclitaxel-combined-tislelizumab-for-recurrent-ovarian-cancer-progressing-within-6-12-months-after-the-last-platinum-line-566
https://sgo.broadcastmed.io/p/s/a-phase-ii-trial-of-stenoparib-2x-121-a-novel-dual-tankyrase-and-parp-inhibitor-in-advanced-recurrent-ovarian-cancer-567
https://sgo.broadcastmed.io/p/s/digital-inequities-and-ovarian-cancer-treatment-and-survival-568
https://sgo.broadcastmed.io/p/s/exploring-social-media-use-and-preferences-among-gynecologic-oncology-patients-for-obtaining-health-information-a-survey-study-569
https://sgo.broadcastmed.io/p/s/an-objective-evaluation-of-this-is-our-lane-a-society-of-gynecologic-oncology-diversity-inclusion-and-health-equity-committee-blog-570
https://sgo.broadcastmed.io/p/s/health-literacy-of-patients-choosing-to-engage-in-a-mobile-health-patient-engagement-application-571
https://sgo.broadcastmed.io/p/s/prognosis-of-patients-who-become-pregnancy-after-achieving-a-complete-response-with-fertility-sparing-treatment-in-early-endometrial-cancer-gynecologic-oncology-research-investigators-collaboration-st-572
https://sgo.broadcastmed.io/p/s/overall-and-physician-level-variability-in-trends-of-salpingectomy-for-interval-sterilization-573
https://sgo.broadcastmed.io/p/s/cesarean-hysterectomy-for-placenta-accreta-spectrum-temporal-trends-in-use-of-adjunct-procedures-574
https://sgo.broadcastmed.io/p/s/quantifying-opportunities-to-reduce-high-grade-serous-ovarian-cancer-via-opportunistic-salpingectomy-575
https://sgo.broadcastmed.io/p/s/feasibility-and-impact-of-an-exercise-program-on-cancer-cachexia-in-patients-with-gynecologic-primary-malignancies-576
https://sgo.broadcastmed.io/p/s/post-operative-complications-among-endometriosis-patients-undergoing-surgical-management-for-stage-1-endometrial-cancer-acs-nsqip-study-577
https://sgo.broadcastmed.io/p/s/evaluating-perioperative-self-reported-sleep-quality-in-patients-with-a-gynecologic-malignancy-578
https://sgo.broadcastmed.io/p/s/same-day-discharge-after-minimally-invasive-interval-debulking-surgery-in-advanced-stage-ovarian-cancer-579
https://sgo.broadcastmed.io/p/s/fluzoparib-plus-apatinib-maintenance-in-patients-with-platinum-sensitive-recurrent-ovarian-cancer-who-had-received-first-line-maintenance-with-a-parp-inhibitor-flash-a-single-arm-exploratory-triala-581
https://sgo.broadcastmed.io/p/s/the-safety-and-efficacy-of-cadonilimab-in-advanced-recurrent-or-metastatic-cervical-cancer-a-multicenter-prospective-real-world-study-582
https://sgo.broadcastmed.io/p/s/post-hoc-tipping-point-and-multiple-imputation-analyses-to-determine-the-impact-of-early-censored-patients-in-the-engot-en6-nsgogog-3031ruby-trial-583
https://sgo.broadcastmed.io/p/s/understanding-the-impact-of-obesity-and-race-on-pembrolizumab-response-in-endometrial-cancer-584
https://sgo.broadcastmed.io/p/s/evaluation-of-immunotherapy-response-in-the-radiated-field-in-patients-with-recurrent-endometrial-and-cervical-cancer-585
https://sgo.broadcastmed.io/p/s/frontline-immunotherapy-combined-with-radiation-and-chemotherapy-in-high-risk-endometrial-cancer-fierce-586
https://sgo.broadcastmed.io/p/s/phase-ib-trial-of-the-bmi-1-inhibitor-ptc596-unesbulin-plus-neoadjuvant-paclitaxel-carboplatin-in-advanced-ovarian-cancer-587
https://sgo.broadcastmed.io/p/s/enlonstobart-sg001-plus-platinum-based-chemotherapy-a-bevacizumab-for-first-line-treatment-of-pd-l1-positive-recurrentmetastatic-cervical-cancer-safety-run-in-results-of-the-phase-iii-randomized-doubl-588
https://sgo.broadcastmed.io/p/s/gynecologic-cancers-in-tumor-agnostic-trials-keys-to-regulatory-approval-589
https://sgo.broadcastmed.io/p/s/accelerating-breakthroughs-how-a-clinical-trial-fast-track-program-is-expanding-access-to-critical-cancer-treatments-590
https://sgo.broadcastmed.io/p/s/identifying-and-breaking-racial-and-ethnic-barriers-enhancing-access-and-equity-in-the-care-of-patients-with-gynecologic-malignancies-591
https://sgo.broadcastmed.io/p/s/demographic-changes-impacting-survival-in-uterine-cancer-from-2010-to-2021-592
https://sgo.broadcastmed.io/p/s/shortened-time-to-diagnostic-imaging-after-symptomatic-presentation-does-not-appear-to-impact-survival-from-ovarian-cancer-a-g-computation-analysis-of-administrative-data-593
https://sgo.broadcastmed.io/p/s/the-hidden-divide-examining-inequities-in-healthcare-provider-training-and-practices-594
https://sgo.broadcastmed.io/p/s/phase-i-clinical-trial-assessing-the-safety-and-feasibility-of-intramuscular-pngvl4a-crte6e7l2-and-ta-cin-administration-for-the-treatment-of-patients-with-hpv16-plus-atypical-squamous-cells-of-unknow-595
https://sgo.broadcastmed.io/p/s/use-and-outcomes-of-hormonal-therapy-for-advanced-stage-low-grade-serous-ovarian-carcinoma-596
https://sgo.broadcastmed.io/p/s/real-world-adherence-to-guideline-based-therapy-in-early-stage-mucinous-ovarian-cancer-597
https://sgo.broadcastmed.io/p/s/oncologic-and-pregnancy-outcomes-in-patients-receiving-fertility-sparing-treatment-for-endometrial-intraepithelial-hyperplasia-and-low-grade-endometrial-cancer-598
https://sgo.broadcastmed.io/p/s/rising-incidence-of-advanced-stage-high-risk-uterine-cancer-disproportionate-impact-on-minority-populations-599
https://sgo.broadcastmed.io/p/s/disparities-in-not-recommending-chemotherapy-for-individuals-with-newly-diagnosed-advanced-endometrial-cancer-due-to-patient-risk-factors-600
https://sgo.broadcastmed.io/p/s/uterine-cancer-incidence-overtakes-colorectal-cancer-disproportionately-impacting-minority-women-in-the-united-states-601
https://sgo.broadcastmed.io/p/s/barriers-to-timely-diagnosis-and-treatment-of-endometrial-cancer-the-impact-of-social-determinants-of-health-602
https://sgo.broadcastmed.io/p/s/leveraging-the-nf-kbhe4-axis-identification-of-a-potential-mechanism-of-action-for-novel-next-generation-proteosome-inhibitor-ur238-on-ovarian-cancer-biomarker-603
https://sgo.broadcastmed.io/p/s/the-impact-of-jak1-mutations-and-mhc-i-expression-on-response-to-immune-checkpoint-inhibition-in-endometrial-cancer-604
https://sgo.broadcastmed.io/p/s/mechanism-of-action-and-therapeutic-targeting-of-parp7-in-endometrial-cancers-605
https://sgo.broadcastmed.io/p/s/prognostic-significance-of-systemic-immune-inflammation-index-sii-in-endometrial-cancer-highlighting-the-predictive-value-of-post-chemotherapy-sii-for-survival-outcomes-606
https://sgo.broadcastmed.io/p/s/updated-duration-of-response-for-patients-receiving-dostarlimab-plus-carboplatin-paclitaxel-treatment-compared-with-patients-receiving-placebo-plus-carboplatin-paclitaxel-in-the-engot-en6-nsgogog-3031-607
https://sgo.broadcastmed.io/p/s/should-lymph-node-staging-be-tailored-according-to-molecular-profile-in-endometrial-cancer-608
https://sgo.broadcastmed.io/p/s/the-utility-of-circulating-tumor-dna-for-detecting-recurrence-during-surveillance-in-patients-with-high-risk-uterine-cancer-609
https://sgo.broadcastmed.io/p/s/differences-in-therapeutic-biomarker-expression-and-disparities-in-genetic-testing-among-black-and-white-women-with-uterine-cancer-610
https://sgo.broadcastmed.io/p/s/outpatient-palliative-care-screening-a-pilot-study-in-a-gynecology-oncology-clinic-611
https://sgo.broadcastmed.io/p/s/an-intervention-to-improve-rates-of-code-status-discussion-and-documentation-for-gynecologic-oncology-inpatients-612
https://sgo.broadcastmed.io/p/s/the-cost-of-relief-complication-rates-in-a-large-cohort-of-gynecologic-oncology-patients-with-malignant-ureteral-obstruction-613
https://sgo.broadcastmed.io/p/s/financial-navigation-in-gynecologic-oncology-a-mixed-methods-study-614
https://sgo.broadcastmed.io/p/s/fwc-coffee-chat-and-recap-622
https://sgo.broadcastmed.io/p/s/kgog-623
https://sgo.broadcastmed.io/p/s/mothers-room-624
https://sgo.broadcastmed.io/p/s/mothers-room-625
https://sgo.broadcastmed.io/p/s/mothers-room-626
https://sgo.broadcastmed.io/p/s/mothers-room-627